"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04333550","Application of Desferal to Treat COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Deferoxamine","Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay","Kermanshah University of Medical Sciences","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1398.1224","April 2020","September 2020","March 2021","April 3, 2020",,"April 6, 2020","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04333550"
2,"NCT04331509","COVID-19 Symptom Tracker",,"Recruiting","No Results Available","COVID-19","Other: No Intervention","Physical health symptoms|Lack of physical health symptoms|Fever","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","All","18 Years and older   (Adult, Older Adult)",,"10000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Symptom tracker","March 23, 2020","March 23, 2022","March 23, 2022","April 2, 2020",,"April 6, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04331509"
3,"NCT04333407","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","C-19-ACS","Not yet recruiting","No Results Available","COVID-19","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","Primary Efficacy Outcome|Secondary Efficacy Outcome 1|Secondary Efficacy Outcome 2|Secondary Efficacy Outcome 3","Imperial College London","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","3170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20HH5868","March 31, 2020","March 30, 2021","March 30, 2021","April 3, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04333407"
4,"NCT04291053","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Huaier Granule","Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function","Tongji Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJ-IRB20200205","April 1, 2020","August 1, 2020","September 1, 2020","March 2, 2020",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04291053"
5,"NCT04324489","DAS181 for Severe COVID-19: Compassionate Use",,"Recruiting","No Results Available","COVID-19","Drug: DAS181","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAS181-SARS-CoV-2","March 6, 2020","April 25, 2020","April 30, 2020","March 27, 2020",,"April 2, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04324489"
6,"NCT04323228","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","ONSCOVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","King Saud University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","ONS_COVID-19","April 1, 2020","October 1, 2020","October 30, 2020","March 26, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04323228"
7,"NCT04335123","Study of Open Label Losartan in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00145514","March 25, 2020","September 2020","October 2020","April 6, 2020",,"April 6, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04335123"
8,"NCT04333420","OPEN LABEL, RANDOMIZED PHASE II/III STUDY OF IFX-1 IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA","PANAMO","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only","Change in PaO2/FiO2|Patients achieving early response","InflaRx GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFX-1-P2.9","March 31, 2020","October 31, 2020","December 31, 2020","April 3, 2020",,"April 3, 2020","University Amsterdam, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04333420"
9,"NCT04321421","Hyperimmune Plasma for Critical Patients With COVID-19","COV19-PLASMA","Active, not recruiting","No Results Available","COVID-19","Other: hyperimmune plasma","death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response","Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA|OSPEDALE MAGGIORE LODI|OSPEDALE ASST CREMONA","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCCSSanMatteoH","March 17, 2020","May 31, 2020","May 31, 2020","March 25, 2020",,"March 25, 2020","Catherine Klersy, Pavia, PV, Italy",,"https://ClinicalTrials.gov/show/NCT04321421"
10,"NCT04325633","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","ENACOVID","Not yet recruiting","No Results Available","COVID-19","Drug: 1: Naproxen|Drug: 2: Standard of care","Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","584","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200387","March 27, 2020","April 27, 2021","June 27, 2021","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04325633"
11,"NCT04323332","Traditional Chinese Medicine for Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Traditional Chinese Medicine Prescription","Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","up to 85 Years   (Child, Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020XLA015-1","March 2020","March 2020","April 2020","March 26, 2020",,"March 26, 2020","Hao Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04323332"
12,"NCT04306497","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","CTOROTSADTOC","Recruiting","No Results Available","COVID-19","Drug: TCM prescriptions","The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score","Jiangsu Famous Medical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)",,"340","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","JSZYJ202001","March 2, 2020","May 2020","May 2020","March 13, 2020",,"March 17, 2020","Huai'an fourth people's Hospital, Huaian, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04306497"
13,"NCT04287686","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19",,"Withdrawn","No Results Available","COVID-19","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIRH-APN01","February 2020","April 2020","April 2020","February 27, 2020",,"March 17, 2020","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04287686"
14,"NCT04324996","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Clinical response|Side effects in the treatment group","Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ChongqingPublicHMC","March 21, 2020","May 31, 2020","September 30, 2020","March 27, 2020",,"March 27, 2020","Chongqing Public Health Medical Center, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04324996"
15,"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051355","April 1, 2020","December 31, 2020","December 31, 2021","April 1, 2020",,"April 1, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04329832"
16,"NCT04331171","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID CALL 15","Recruiting","No Results Available","COVID-19","Device: Web application users","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Weprom|Institut Pasteur|Assistance Publique - Hôpitaux de Paris|DOCAPOST|Direction Générale de l'Offre de Soins","All","18 Years and older   (Adult, Older Adult)",,"3000000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WP-2020-02","March 17, 2020","March 31, 2020","July 31, 2020","April 2, 2020",,"April 6, 2020","All French Emergency services, Le Mans, France",,"https://ClinicalTrials.gov/show/NCT04331171"
17,"NCT04317092","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","TOCIVID-19","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab Injection","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples","All","Child, Adult, Older Adult","Phase 2","330","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCIVID-19|2020-001110-38","March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",,"March 20, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04317092"
18,"NCT04328285","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","COVIDAXIS","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","All","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20PH061|2020-001188-96","March 30, 2020","November 30, 2020","November 30, 2020","March 31, 2020",,"March 31, 2020","CHU d'Angers, Angers, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04328285"
19,"NCT04330586","A Trial of Ciclesonide in Adults With Mild COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure","Korea University Guro Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KUMC-COVID-19","April 1, 2020","June 30, 2020","September 30, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330586"
20,"NCT04275947","The COVID-19 Mobile Health Study (CMHS)","CMHS","Recruiting","No Results Available","COVID-19","Other: nCapp, a cell phone-based auto-diagnosis system","Accuracy of nCapp COVID-19 risk diagnostic model","Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution","All","18 Years to 90 Years   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAALC-008-CMHS","February 14, 2020","April 30, 2020","May 31, 2020","February 19, 2020",,"February 19, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04275947"
21,"NCT04331899","Mild COVID-19 Peginterferon Lambda","COVID-Lambda","Not yet recruiting","No Results Available","COVID-19","Drug: Peginterferon Lambda-1a|Other: Standard of Care Treatment","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Stanford University","All","18 Years to 64 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","55619","April 15, 2020","May 31, 2021","May 31, 2022","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331899"
22,"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent change in C-reactive protein (CRP) levels|Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Change in serum CRP levels|Incidence of serious adverse events|Incidence of Grade 4 neutropenia (ANC <500/mm3)|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Incidence of gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-COV-2040","March 18, 2020","March 9, 2021","April 1, 2021","March 19, 2020",,"April 6, 2020","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Facility 2, Manhasset, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04315298"
23,"NCT04330638","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COV-AID","Not yet recruiting","No Results Available","COVID-19","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre","All","8 Years to 80 Years   (Child, Adult, Older Adult)","Phase 4","342","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-AID","April 2020","September 2020","December 2020","April 1, 2020",,"April 1, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|University Hospital Ghent, Gent, Belgium|University Hospital Brussels, Jette, Belgium|University Hospital Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT04330638"
24,"NCT04332081","Hyperbaric Oxygen for COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Device: hyperbaric oxygen therapy (HBOT)","Mortality|Days on invasive mechanical ventilation","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00399","April 2020","July 2020","July 2020","April 2, 2020",,"April 2, 2020","NYU Winthrop Hospital, Mineola, New York, United States",,"https://ClinicalTrials.gov/show/NCT04332081"
25,"NCT04304313","A Pilot Study of Sildenafil in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sildenafil citrate tablets","Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GST-G1","February 9, 2020","March 1, 2020","November 9, 2020","March 11, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04304313"
26,"NCT04326920","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","SARPAC","Recruiting","No Results Available","COVID-19","Drug: Sargramostim|Other: Control","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","University Hospital, Ghent|Flanders Institute of Biotechnology","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARPAC","March 24, 2020","October 31, 2020","December 31, 2020","March 30, 2020",,"April 2, 2020","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT04326920"
27,"NCT04334512","A Study of Quintuple Therapy to Treat COVID-19 Infection","HAZCpaC","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Successful treatment as determined by Negative Test and resolution of symptoms|Safety of Quintuple Therapy","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRG-044","April 2020","April 2021","July 2021","April 6, 2020",,"April 6, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04334512"
28,"NCT04327674","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19",,"Recruiting","No Results Available","COVID-19",,"FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.","University of Aarhus","All","18 Years and older   (Adult, Older Adult)",,"375","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-FLUS","March 14, 2020","May 15, 2020","May 15, 2020","March 31, 2020",,"March 31, 2020","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark",,"https://ClinicalTrials.gov/show/NCT04327674"
29,"NCT04329923","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","PATCH","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Ravi Amaravadi, MD|University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","842838","April 6, 2020","April 1, 2021","December 1, 2021","April 1, 2020",,"April 1, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04329923"
30,"NCT04330690","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","CATCO","Active, not recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir","Efficacy of Intervention|Time to improvement of one catergory from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","Sunnybrook Health Sciences Centre|AbbVie","All","6 Months and older   (Child, Adult, Older Adult)","Phase 2","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2114","March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",,"April 1, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04330690"
31,"NCT04318418","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","Not yet recruiting","No Results Available","COVID-19",,"Severe COVID-19|Death","Neuromed IRCCS","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DEP_012020","March 23, 2020","April 10, 2020","April 30, 2020","March 24, 2020",,"March 24, 2020","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",,"https://ClinicalTrials.gov/show/NCT04318418"
32,"NCT04285801","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study",,"Completed","No Results Available","COVID-19",,"28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2020.059","February 14, 2020","February 25, 2020","February 25, 2020","February 26, 2020",,"March 10, 2020","Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04285801"
33,"NCT04304053","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","HCQ4COV19","Recruiting","No Results Available","COVID-19","Drug: Antiviral treatment and prophylaxis|Other: Standard Public Health measures","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug","Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut","All","18 Years and older   (Adult, Older Adult)","Phase 3","3040","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HCQ4COV19|2020-001031-27","March 18, 2020","June 15, 2020","June 15, 2020","March 11, 2020",,"March 24, 2020","CAP II Sant Fèlix, Sabadell, Barcelona, Spain|Gerència Territorial Catalunya Central, Sant Fruitós De Bages, Barcelona, Spain|Centre de Salut Isabel Roig-Casernes de Sant Andreu, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04304053"
34,"NCT04319315","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak",,"Recruiting","No Results Available","COVID-19","Other: survey","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Assiut University","All","25 Years to 65 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AssiutU-3-2020","March 11, 2020","March 16, 2020","March 16, 2020","March 24, 2020",,"March 24, 2020","Assiut University Hospitals, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04319315"
35,"NCT04321993","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)|Drug: Sarilumab (anti-IL-6 receptor)","Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAIL-004","March 2020","February 2021","July 2021","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04321993"
36,"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","All","45 Years and older   (Adult, Older Adult)","Phase 3","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051360","April 1, 2020","December 31, 2020","December 31, 2021","April 6, 2020",,"April 6, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04334382"
37,"NCT04329611","Hydroxychloroquine to Prevent Covid19 Pneumonia (ALBERTA HOPE-Covid19)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality","Dr. Michael Hill|University of Calgary","All","18 Years and older   (Adult, Older Adult)","Phase 3","1660","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABCOV-01","April 8, 2020","July 31, 2020","August 31, 2020","April 1, 2020",,"April 6, 2020","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04329611"
38,"NCT04335136","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","APN01-COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: RhACE2 APN01|Drug: Physiological saline solution","Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Apeiron Biologics","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","APN01-01-COVID19","April 2020","September 2020","November 2020","April 6, 2020",,"April 6, 2020","Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany",,"https://ClinicalTrials.gov/show/NCT04335136"
39,"NCT04331366","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","GO2 PEEP","Not yet recruiting","No Results Available","COVID-19","Device: GO2 PEEP MOUTHPIECE","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00000381","April 2020","April 2020","April 2020","April 2, 2020",,"April 2, 2020","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04331366"
40,"NCT04333355","Safety in Convalescent Plasma Transfusion to COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Lung infiltrates|Viral load of SARS-CoV-2","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PC-TecSalud Fase I","April 15, 2020","December 20, 2020","April 30, 2021","April 3, 2020",,"April 3, 2020","Hospital San José, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04333355"
41,"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","Not yet recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0515","April 3, 2020","July 1, 2020","December 1, 2020","April 2, 2020",,"April 2, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04331795"
42,"NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Rate of COVID-19 positive conversion|Time-to-first clinical event","Baylor Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","360","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","020-132","April 3, 2020","July 30, 2020","July 30, 2020","April 3, 2020",,"April 3, 2020","Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04333225"
43,"NCT04335084","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","HELPCOVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Prevention of COVID-19 measured by negative testing with RT-PCR|Safety as determined by blood pressure readings|Safety as determined by presence of side effects","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRG-042","April 2020","April 2021","July 2021","April 6, 2020",,"April 6, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04335084"
44,"NCT04313023","The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2",,"Not yet recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Prevention of COVID-19","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PUL-042-501","April 2020","September 2020","October 2020","March 18, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04313023"
45,"NCT04307693","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine","Asan Medical Center","All","16 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2020-0472-0001","March 11, 2020","May 2020","May 2020","March 13, 2020",,"March 13, 2020","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04307693"
46,"NCT04323631","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Number patients developing severe infection or death","Rambam Health Care Campus|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1116","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0154-20-RMB","March 2020","December 2020","December 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04323631"
47,"NCT04331834","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","PrEP_COVID","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebos","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PrEP_COVID","April 3, 2020","October 3, 2020","October 30, 2020","April 2, 2020",,"April 2, 2020","ISGlobal, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04331834"
48,"NCT04292899","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Proportion of Participants With Treatment Emergent Adverse Events Leading to Study Drug Discontinuation","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5773|2020-000841-15","March 6, 2020","May 2020","May 2020","March 3, 2020",,"April 2, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place, New Brunswick, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|King's College Hospital NHS Trust, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292899"
49,"NCT04334980","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: bacTRL-Spike","Frequency of Adverse Events|SARS-CoV-2 Antibodies|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination","Symvivo Corporation","All","19 Years to 55 Years   (Adult)","Phase 1","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","bacTRL-Spike-1","April 30, 2020","August 31, 2021","December 31, 2021","April 6, 2020",,"April 6, 2020","Vaccine Evaluation Center, BC Children's Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04334980"
50,"NCT04312997","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|All cause mortality","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUL-042-502","April 2020","September 2020","October 2020","March 18, 2020",,"March 24, 2020","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04312997"
51,"NCT04329572","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","Azidus Brasil|PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","400","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0320OR","April 3, 2020","May 31, 2020","June 30, 2020","April 1, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04329572"
52,"NCT04292730","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",,"Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","Proportion of Participants Discharged by Day 14|Proportion of Participants With Treatment Emergent Adverse Events Leading to Study Drug Discontinuation","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5774|2020-000842-32","March 15, 2020","May 2020","May 2020","March 3, 2020",,"April 2, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|Cook County General Hospital, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, Hillsborough, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place, New Brunswick, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|UTSW Medical Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|University Clinic Düsseldorf, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|King's College Hospital NHS Trust, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292730"
53,"NCT04331470","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Clear chest CT-scan|PCR test|Physical statues of patient","Fasa University of Medical Sciences","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","97548","March 31, 2020","April 20, 2020","May 20, 2020","April 2, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04331470"
54,"NCT04315987","NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: NestCell®","Disappear time of ground-glass shadow in the lungs|Rate of mortality within 28-days|Change of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group","Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOPE","April 2020","May 2020","June 2020","March 20, 2020",,"March 31, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04315987"
55,"NCT04305106","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","BEST-RCT","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Bevacizumab","The time from randomization to clinical improvement","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","QLEmer","March 17, 2020","June 30, 2020","July 31, 2020","March 12, 2020",,"March 26, 2020","Qilu Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04305106"
56,"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ)|Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Organ Failure-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42380|2020-001154-22","April 3, 2020","August 31, 2021","September 30, 2021","March 25, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04320615"
57,"NCT04313322","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells",,"Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome|CT Scan|RT-PCR results","Stem Cells Arabia","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","March 16, 2020","June 30, 2020","September 30, 2020","March 18, 2020",,"March 18, 2020","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04313322"
58,"NCT04308317","Tetrandrine Tablets Used in the Treatment of COVID-19","TT-NPC","Enrolling by invitation","No Results Available","Corona Virus Disease 2019,COVID-19","Drug: Tetrandrine","Survival rate|body temperature","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TT-NPC","March 5, 2020","March 1, 2021","May 1, 2021","March 16, 2020",,"March 16, 2020","Tetrandrine Tablets, Jinhua, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04308317"
59,"NCT04273529","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: thalidomide|Drug: placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-M-T","February 20, 2020","May 30, 2020","June 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273529"
60,"NCT04273581","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: placebo|Drug: Thalidomide","Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-S-T","February 18, 2020","April 30, 2020","May 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273581"
61,"NCT04312464","Myocardial Damage in COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|Cardiovascular Diseases","Other: non","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MD-COVID-19","January 1, 2020","March 15, 2020","March 18, 2020","March 18, 2020",,"March 18, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04312464"
62,"NCT04329650","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Siltuximab|Drug: Methylprednisolone","Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.","Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SILCOR-COVID-19","April 1, 2020","May 20, 2020","May 20, 2020","April 1, 2020",,"April 6, 2020","Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04329650"
63,"NCT04331600","ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020","QUARANTINE2020","Not yet recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate|Other: Telemedicine","COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications","Wroclaw Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QUARANTINE2020","April 6, 2020","September 30, 2020","December 31, 2020","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331600"
64,"NCT04280588","Fingolimod in COVID-19",,"Recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Fingolimod 0.5 mg","The change of pneumonia severity on X-ray images","First Affiliated Hospital of Fujian Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCTA, ECFAH of FMU [2020]027","February 22, 2020","July 1, 2020","July 1, 2020","February 21, 2020",,"February 21, 2020","Wan-Jin Chen, Fuzhou, China",,"https://ClinicalTrials.gov/show/NCT04280588"
65,"NCT04325061","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome Caused by COVID-19","Drug: Dexamethasone","60-day mortality|Ventilator-free days","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001278-31","April 1, 2020","October 30, 2020","October 30, 2020","March 27, 2020",,"April 1, 2020","Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Universitario La Fe, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04325061"
66,"NCT04315896","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","HYDRA","Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HidroxycloroquinaCOVID19","March 23, 2020","October 31, 2020","March 22, 2021","March 20, 2020",,"March 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04315896"
67,"NCT04335201","Defibrotide in COVID-19 Pneumonia","DEFI-VID19","Not yet recruiting","No Results Available","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","Drug: Defibrotide Injection","to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DEFI-VID19","April 6, 2020","September 30, 2020","December 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335201"
68,"NCT04329559","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study",,"Recruiting","No Results Available","COVID-19|Liver Cirrhosis",,"All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth People’s Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People’s Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CHESS2002","March 30, 2020","June 29, 2020","June 29, 2021","April 1, 2020",,"April 1, 2020","Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China",,"https://ClinicalTrials.gov/show/NCT04329559"
69,"NCT04318301","Hypertension in Patients Hospitalized With COVID-19","HT-COVID19","Active, not recruiting","No Results Available","COVID-19|Hypertension",,"Rate of Death|the severity of pneumonia","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Zhenhuazen2018","March 21, 2020","March 28, 2020","March 30, 2020","March 23, 2020",,"March 24, 2020","Hankou Hospital, Hankou, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04318301"
70,"NCT04328441","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","BCG-CORONA","Recruiting","No Results Available","COVID-19","Drug: BCG Vaccine|Drug: Placebo","Health Care Workers absenteeism|The cumulative incidence of documented SARS-CoV-2 infection|The number of days of unplanned absenteeism, because of documented SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS-CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (≥38 gr C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented SARS-CoV-2 infection|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection|The cumulative incidence of Hospital Admission for any reason|The cumulative incidence of Hospital Admission due to documented SARS-CoV-2 infection|The incidence and magnitude of SARS-CoV-2 antibodies at the end of the study period","UMC Utrecht|Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NL73249.041.20","March 25, 2020","October 25, 2020","December 25, 2020","March 31, 2020",,"April 3, 2020","Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04328441"
71,"NCT04332107","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","ACTION","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Azithromycin|Drug: Placebos","Hospitalization|Viral load|Mortality","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 3","2271","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30504","April 1, 2020","July 30, 2020","July 30, 2021","April 2, 2020",,"April 6, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04332107"
72,"NCT04334044","Treatment of SARS Caused by COVID-19 With Ruxolitinib",,"Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate","Grupo Cooperativo de Hemopatías Malignas","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAL 345/2020","April 1, 2020","June 1, 2020","June 1, 2020","April 3, 2020",,"April 3, 2020","Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico",,"https://ClinicalTrials.gov/show/NCT04334044"
73,"NCT04332913","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","TOSCA","Not yet recruiting","No Results Available","COVID-19 Pneumonia",,"Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases","University of L'Aquila","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0064468/20","April 1, 2020","December 31, 2020","March 31, 2021","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04332913"
74,"NCT04328493","The Vietnam Chloroquine Treatment on COVID-19","VICO","Not yet recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Drug: Chloroquine phosphate","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|Time to viral PCR negative from rectal swab|fever clearance time|Ordinal outcome scale|Development of ARDS","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID","April 1, 2020","April 1, 2021","April 1, 2022","March 31, 2020",,"March 31, 2020","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT04328493"
75,"NCT04330521","Impact of the Coronavirus (COVID-19) on Patients With Cancer",,"Not yet recruiting","No Results Available","Cancer|COVID-19",,"Number of participants who fill out the survey and participate in the semi-structured interviews.","Stanford University","All","18 Years to 99 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","55596","April 2020","May 2022","May 2022","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330521"
76,"NCT04317040","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","SAC-COVID","Not yet recruiting","No Results Available","Severe Coronavirus Disease (COVID-19)","Drug: CD24Fc|Drug: Placebo","Improvement of COVID-19 disease status|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|All cause of death|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of oxygen therapy|Length of hospital stay|Absolute lymphocyte count","OncoImmune, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CD24Fc-007","May 2020","May 2021","May 2022","March 20, 2020",,"March 23, 2020","Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04317040"
77,"NCT04334005","Vitamin D on Prevention and Treatment of COVID-19","COVITD-19","Not yet recruiting","No Results Available","Patients Infected With COVID-19","Dietary Supplement: Vitamin D","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery","Universidad de Granada","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVITD-19","April 10, 2020","June 30, 2020","June 30, 2020","April 3, 2020",,"April 3, 2020","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04334005"
78,"NCT04288102","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)",,"Recruiting","No Results Available","Corona Virus Disease 2019(COVID-19)","Biological: MSCs|Biological: Saline containing 1% Human serum albumin（solution of MSC）","Size of lesion area and severity of pulmonary fibrosis by chest CT|Proportion of patients in each classification of clinical critical treatment index|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Blood oxygen saturation|CD4+ T cell count and cytokine level|Side effects in the MSCs treatment group","Beijing 302 Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Wuhan Huoshenshan Hospital, Wuhan, China|Maternal and Child Health Hospital of Hubei Province|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University|Wuhan Union Hospital, China|West China Hospital|Tianjin Haihe Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-013-D","March 5, 2020","December 31, 2020","December 31, 2021","February 28, 2020",,"March 23, 2020","Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04288102"
79,"NCT04286503","The Clinical Study of Carrimycin on Treatment Patients With COVID-19",,"Not yet recruiting","No Results Available","Novel Coronavirus Infectious Disease (COVID-19)","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment","Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BeijingYouan Hospital","February 23, 2020","February 28, 2021","February 28, 2021","February 27, 2020",,"February 27, 2020",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04286503"
80,"NCT04293692","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus",,"Withdrawn","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes","Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200225","February 24, 2020","February 25, 2020","February 25, 2020","March 3, 2020",,"March 18, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04293692"
81,"NCT04329507","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)",,"Not yet recruiting","No Results Available","COVID-19|Respiratory Disease","Diagnostic Test: Breath test","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","NHS Lothian","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282014","March 25, 2020","March 25, 2020","March 25, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04329507"
82,"NCT04333472","Piclidenoson for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection","Drug: Piclidenoson","Duration of viral shedding in days|Time to clinical recovery (TTCR) in days|Treatment-emergent adverse events (AEs)|Requirement for non-invasive or mechanical ventilation|Length of hospital stay in days|Estimated PaO2/FiO2 ratio on day of discharge|All-cause mortality|Patients reaching undetectable COVID-19 virus levels in respiratory secretions|Duration of symptoms and signs of respiratory infection in days|Need for supportive respiratory management|Viral load|Treatment-emergent serious AEs (SAEs)|AEs leading to withdrawal|Treatment-emergent abnormalities in clinical laboratory parameters","Can-Fite BioPharma|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAN-COR-1","April 6, 2020","June 6, 2020","July 6, 2020","April 3, 2020",,"April 3, 2020","Rabin Medical Center, Petah tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04333472"
83,"NCT04335305","Checkpoint Blockade in COVID-19 Pandemic","COPERNICO","Not yet recruiting","No Results Available","COVID-19|Pneumonia, Viral","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Percentage of patients with normalization of SpO2 ≥96%|Proportion of patients with temperature < 37,5 °C armpit.|Proportion of patients discharged from the emergency department and classified as low risk|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in SARS-CoV-2 RT-PCR test|Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)","MedSIR","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedOPP376","March 30, 2020","May 15, 2020","May 15, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335305"
84,"NCT04273321","Efficacy and Safety of Corticosteroids in COVID-19",,"Recruiting","No Results Available","COVID-19|Novel Coronavirus Pneumonia","Drug: Methylprednisolone","the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days","Beijing Chao Yang Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Methylprednisolone in COVID-19","February 14, 2020","May 1, 2020","May 30, 2020","February 18, 2020",,"April 1, 2020","Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China",,"https://ClinicalTrials.gov/show/NCT04273321"
85,"NCT04333628","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Plaquenil","Drug: chloroquine|Other: standard care","Reducing virus duration (viral shedding)|Reducing the number of patients going from asymptomatic to moderately disease","HaEmek Medical Center, Israel","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMC 0045-20","April 2020","April 2021","December 2021","April 3, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04333628"
86,"NCT04331665","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Pneumonia","Drug: Ruxolitinib","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|All cause mortality rate|Average duration of hospital stay|Number of occurrence of secondary infections","University Health Network, Toronto","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U-DEPLOY: RUX-COVID|20-5315","April 6, 2020","October 30, 2020","January 31, 2021","April 2, 2020",,"April 3, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04331665"
87,"NCT04318444","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants with symptomatic, lab-confirmed COVID-19.","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9676","March 2020","March 2021","March 2022","March 24, 2020",,"March 25, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04318444"
88,"NCT04323345","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus",,"Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Natural Honey|Other: Standard Care","Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results","Misr University for Science and Technology","All","5 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MUST23032020","March 25, 2020","April 25, 2020","May 10, 2020","March 26, 2020",,"March 26, 2020","Mahmoud Tantawy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04323345"
89,"NCT04318015","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","PHYDRA","Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ProfilaxisCOVID","April 1, 2020","December 31, 2020","March 31, 2021","March 23, 2020",,"March 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04318015"
90,"NCT04328272","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","All","18 Years to 50 Years   (Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Ath/ct101/22/3","March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",,"https://ClinicalTrials.gov/show/NCT04328272"
91,"NCT04327531","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",,"Active, not recruiting","No Results Available","COVID-19|Physician-Patient Relations","Behavioral: turkish physicians","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Kanuni Sultan Suleyman Training and Research Hospital","All","25 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","turkishcovid19","March 26, 2020","April 26, 2020","April 28, 2020","March 31, 2020",,"April 2, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04327531"
92,"NCT04335019","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","eChoVid","Not yet recruiting","No Results Available","2019-nCoV (COVID-19)|Interstitial Pneumonia","Other: Pulmonary ultrasound","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","APHP200390|2020-A00768-31","April 2020","April 2020","May 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335019"
93,"NCT04334291","International COVID19 Clinical Evaluation Registry,","HOPE COVID 19","Recruiting","No Results Available","COVID 19","Combination Product: Observational (registry)","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","IVAN J NUÑEZ GIL|St Carlos Hospital, Madrid, Spain","All","Child, Adult, Older Adult",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20/241-E|EUPAS34399","March 23, 2020","May 1, 2020","May 5, 2020","April 6, 2020",,"April 6, 2020","Hospital Lclinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04334291"
94,"NCT04333914","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","IMMUNONCOVID","Not yet recruiting","No Results Available","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care","28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)","Centre Leon Berard","All","18 Years and older   (Adult, Older Adult)","Phase 2","273","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET20-076 - IMMUNONCOVID-20|2020-001373-70","April 2020","June 2020","August 2020","April 3, 2020",,"April 3, 2020","Centre Léon Bérard, Lyon, Rhône, France",,"https://ClinicalTrials.gov/show/NCT04333914"
95,"NCT04323644","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","CovidSurg","Not yet recruiting","No Results Available","COVID-19|Coronavirus|Surgery","Procedure: Surgery","30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","University of Birmingham","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CS-20200324","March 31, 2020","September 30, 2020","September 30, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04323644"
96,"NCT04251767","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection",,"Withdrawn","No Results Available","COVID-19 Complicated With Refractory Intestinal Infections","Other: washed microbiota transplantation|Other: placebo","Number of participants with improvement from severe type to common type","The Second Hospital of Nanjing Medical University","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WMT-YJ-202001","February 5, 2020","April 30, 2020","April 30, 2020","February 5, 2020",,"March 17, 2020","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04251767"
97,"NCT04330144","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)",,"Not yet recruiting","No Results Available","Contact Person From COVID-19 Confirmed Patient","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)","The rate of COVID-19","Gangnam Severance Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2486","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","3-2020-0036","April 1, 2020","March 30, 2021","March 30, 2022","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330144"
98,"NCT04299724","Safety and Immunity of Covid-19 aAPC Vaccine",,"Recruiting","No Results Available","Treat and Prevent Covid-19 Infection","Biological: Pathogen-specific aAPC","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20002","February 15, 2020","July 31, 2023","December 31, 2024","March 9, 2020",,"March 9, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04299724"
99,"NCT04298814","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Endotracheal Intubation","Other: severe covid-19 pneumonia with ET","Success rate of intubation|Infection rate of Anesthesiologist|Extubation time","Tongji Hospital","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVEI","March 7, 2020","May 30, 2020","July 30, 2020","March 6, 2020",,"March 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04298814"
100,"NCT04335097","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","HSC19","Not yet recruiting","No Results Available","COVID 19","Device: Biosensors","Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital","Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|Basque Country University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","127157","April 7, 2020","April 8, 2021","December 20, 2025","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335097"
101,"NCT04324190","DIgital Online SuPport for COVID-19 StrEss","DISPOSE","Not yet recruiting","No Results Available","COVID-19|Psychosocial Stress|Mental Health","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Screening Tool for Psychological Distress (STOP-D) - selected items","Gunther Meinlschmidt|Selfapy GmbH|International Psychoanalytic University Berlin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","IPUB_2020_01","March 2020","June 2021","December 2021","March 27, 2020",,"March 27, 2020","Selfapy GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04324190"
102,"NCT04334850","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","MultiCov","Not yet recruiting","No Results Available","Covid19|Pneumonia","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment","Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life","Assistance Publique - Hôpitaux de Paris|BioMérieux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","194","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200392|2020-001324-33","April 2020","July 2020","August 2020","April 6, 2020",,"April 6, 2020","Intensive care department-Hospital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04334850"
103,"NCT04333693","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Covid-VAS","Not yet recruiting","No Results Available","Vascular Surgical Procedures|COVID-19|Postoperative Complications","Procedure: Vascular surgery","30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-2020-1","April 1, 2020","October 1, 2020","November 1, 2020","April 3, 2020",,"April 3, 2020","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04333693"
104,"NCT04276896","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine",,"Recruiting","No Results Available","Pathogen Infection Covid-19 Infection","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20001","March 24, 2020","July 31, 2023","December 31, 2024","February 19, 2020",,"March 19, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04276896"
105,"NCT04335071","Multicenter, Double-blind, Randomized Controlled Trial of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","CORON-ACT","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Tocilizumab (TCZ)|Drug: Placebo","Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)","University Hospital Inselspital, Berne|Roche Pharma AG","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-00691|2020DR2044","April 2020","October 2020","October 2020","April 6, 2020",,"April 6, 2020","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04335071"
106,"NCT04326725","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia",,"Recruiting","No Results Available","to Evaluate the Efficacy of Hydroxychloroquine Plus vitACD-Zinc as Prevention for COVID19 Infection","Drug: Plaquenil 200Mg Tablet","Protection against COVID-19","Istinye University","All","20 Years to 90 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020-2/1","March 20, 2020","July 1, 2020","September 1, 2020","March 30, 2020",,"March 30, 2020","Istinye University Medical School, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04326725"
107,"NCT04328961","Hydroxychloroquine for COVID-19 PEP",,"Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","University of Washington|New York University|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","STUDY00009750","March 2020","September 30, 2020","October 31, 2020","April 1, 2020",,"April 1, 2020","NYU Langone Health, New York, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04328961"
108,"NCT04333862","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Covid-19","Recruiting","No Results Available","SARS-CoV-2",,"Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00563","March 19, 2020","June 30, 2020","December 31, 2021","April 3, 2020",,"April 3, 2020","Guido Beldi, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333862"
109,"NCT04333953","COVID-19 in Patients With HIV",,"Recruiting","No Results Available","HIV/AIDS|COVID-19|SARS-CoV-2","Other: No intervention","Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury","University of Missouri-Columbia","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","262095","April 1, 2020","October 1, 2020","October 1, 2020","April 3, 2020",,"April 3, 2020","University of Missouri-Columbia, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04333953"
110,"NCT04323514","Use of Ascorbic Acid in Patients With COVID 19",,"Recruiting","No Results Available","Hospitalized Patients With Covid-19 Pneumonia","Dietary Supplement: Vitamin C","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","University of Palermo","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3143","March 13, 2020","March 13, 2021","March 13, 2021","March 26, 2020",,"March 26, 2020","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04323514"
111,"NCT04322188","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","SISCO","Recruiting","No Results Available","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection",,"Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings","A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","v 0.9 16th March 2020","March 19, 2020","May 19, 2020","May 19, 2020","March 26, 2020",,"March 31, 2020","ASST - Papa Giovanni XXIII, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT04322188"
112,"NCT04334252","Descriptive Study Regarding Pre-operative Screening During COVID 19 Pandemia",,"Not yet recruiting","No Results Available","COVID 19","Other: Questionnaire","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JessaH_COVID19_prescreening","April 17, 2020","December 20, 2022","December 20, 2023","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334252"
113,"NCT04316299","Acute Kidney Injury in Patients Hospitalized With COVID-19",,"Completed","No Results Available","COVID-19|Acute Kidney Injury|Kidney Function",,"Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years and older   (Adult, Older Adult)",,"287","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","hkyy2020-005 AKI","February 26, 2020","February 28, 2020","March 8, 2020","March 20, 2020",,"March 30, 2020","Hankou Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04316299"
114,"NCT04318431","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","COVILLE","Not yet recruiting","No Results Available","Covid19","Diagnostic Test: Data collection and rhinopharyngeal swab","Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses","Centre Hospitalier Intercommunal Creteil|ACTIV","All","6 Months to 15 Years   (Child)","Not Applicable","600","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVILLE|2020-A00724-35","April 2020","June 2020","June 2020","March 24, 2020",,"March 26, 2020","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|53 Boulevard De La Liberté, Les Lilas, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|Cabinet du Dr Bodin, Montgeron, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr D'acremont, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France",,"https://ClinicalTrials.gov/show/NCT04318431"
115,"NCT04334460","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects",,"Not yet recruiting","No Results Available","Sars-CoV2","Drug: BLD-2660","Antiviral Activity|Improvement of oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)","Blade Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B-2660-204","May 2020","August 2020","September 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334460"
116,"NCT04320017","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","JOCOVID","Recruiting","No Results Available","COVID-19|Myocardial Injury|Myocarditis","Diagnostic Test: Electrocardiogram and transthoracic echocardiography","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes","Groupe Hospitalier Pitie-Salpetriere","All","16 Years and older   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIC1421-20-05","March 20, 2020","May 20, 2020","May 20, 2020","March 24, 2020",,"March 24, 2020","Clinical Investigation Center Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04320017"
117,"NCT04313127","A Phase I Clinical Trial in 18-60 Adults","APICTH","Active, not recruiting","No Results Available","COVID-19","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune","CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","108","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JSVCT088","March 16, 2020","December 30, 2020","December 20, 2022","March 18, 2020",,"March 31, 2020","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04313127"
118,"NCT04335630","Cardiovascular Manifestations of COVID-19",,"Recruiting","No Results Available","Study Focus: Identify the Prevalence of Cardiovascular Disease and Its Role in Clinical Outcomes of Hospitalized Patients Diagnosed With COVID-19","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications","Memorial Hermann Health System","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HSC-MS-20-0286","March 30, 2020","March 2021","March 2022","April 6, 2020",,"April 6, 2020","Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04335630"
119,"NCT04328012","Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)","COVID MED","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","NIAID COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|ICU level LOS|Mechanical ventilation|survival","Bassett Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1581969","April 1, 2020","January 1, 2021","April 1, 2021","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04328012"
120,"NCT04331574","Renin-Angiotensin System Inhibitors and COVID-19","SARS-RAS","Recruiting","No Results Available","COVID-19|Hypertension|Cardiovascular Diseases",,"Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity","Societa Italiana dell'Ipertensione Arteriosa","All","18 Years to 120 Years   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","SARS-RAS","March 10, 2020","April 10, 2020","April 30, 2020","April 2, 2020",,"April 2, 2020","Spedali Civili di Brescia, Brescia, Italy",,"https://ClinicalTrials.gov/show/NCT04331574"
121,"NCT04333732","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","CROWN CORONA","Not yet recruiting","No Results Available","COVID 19","Drug: Low-dose chloroquine/hydroxychloroquine|Drug: Mid dose chloroquine or hydroxychloroquine|Drug: High does chloroquine or hydroxychloroquine|Drug: Placebo","Symptomatic COVID-19|Peak severity of COVID-19 over the study period","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","55000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","202004xxx","April 2020","February 2021","February 2021","April 3, 2020",,"April 3, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States|Melbourne Medical School, Melbourne, Victoria, Australia|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|University College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04333732"
122,"NCT04321265","Outcomes and Prognostic Factors in COVID-19","COVIP","Recruiting","No Results Available","COVID-19|Elderly Patients|Critical Illness|Survival|Old Age",,"Survival|Fragilty","Heinrich-Heine University, Duesseldorf","All","70 Years and older   (Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-004","March 19, 2020","September 2020","December 2020","March 25, 2020",,"March 27, 2020","Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany",,"https://ClinicalTrials.gov/show/NCT04321265"
123,"NCT04326790","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","GRECCO-19","Not yet recruiting","No Results Available","Corona Virus Disease 19 (Covid 19)","Drug: Colchicine|Drug: Standard treatment","CRP increase to 3 x upper limit of normal|Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee|Maximal concentration of cardiac troponin","National and Kapodistrian University of Athens","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","906295542","April 6, 2020","August 31, 2020","September 30, 2020","March 30, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04326790"
124,"NCT04327206","BCG Vaccination to Protect Healthcare Workers Against COVID-19","BRACE","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)|Febrile Respiratory Illness|Corona Virus Infection|COVID-19","Drug: BCG Vaccine","COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Febrile respiratory illness|Episodes of febrile respiratory illness|Work absenteeism due to febrile respiratory illness|Bed confinement due to febrile respiratory illness|Symptom duration of febrile respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with febrile respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers","Murdoch Childrens Research Institute|Royal Children's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","4170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","62586","March 30, 2020","October 30, 2020","March 30, 2022","March 31, 2020",,"April 2, 2020","Royal Children's Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04327206"
125,"NCT04334265","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019",,"Not yet recruiting","No Results Available","COVID-19","Drug: Anluohuaxian","Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung","Peking University First Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020 research 110","April 1, 2020","June 1, 2020","December 1, 2020","April 6, 2020",,"April 6, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04334265"
126,"NCT04334148","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","HERO-HCQ","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants testing positive for COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events","Duke University|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","15000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Pro00105274","April 2020","July 2020","July 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334148"
127,"NCT04333589","A Prospective Study on Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",,"Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir","Viral nucleic acid test negative conversion rate|Clinical cure rate","Peking University First Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020 research 112","April 1, 2020","June 1, 2020","September 15, 2020","April 3, 2020",,"April 3, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04333589"
128,"NCT04330599","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","COVIDENCE","Not yet recruiting","No Results Available","COVID-19",,"Incidence of suspected, probable or confirmed COVID-19|Incidence of confirmed COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of COVID-19 on participants' financial status|Incidence of physical complications of COVID-19|Impact of COVID-19 on participants' mental well-being","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine","All","16 Years and older   (Child, Adult, Older Adult)",,"12000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDENCE","April 2, 2020","April 1, 2025","April 1, 2025","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330599"
129,"NCT04328480","The ECLA PHRI COLCOVID Trial","COLCOVID","Not yet recruiting","No Results Available","COVID-19","Drug: Colchicine|Other: Local standard of care","All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.","Estudios Clínicos Latino América|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLCOVID version1.2","March 2020","May 30, 2020","June 30, 2020","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04328480"
130,"NCT04311398","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","Huashan Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KY2020-COVID-19","March 14, 2020","June 1, 2020","December 1, 2020","March 17, 2020",,"March 17, 2020","Huashan Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04311398"
131,"NCT04310228","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time","Peking University First Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020YFC0844100","March 8, 2020","May 2020","May 2020","March 17, 2020",,"March 17, 2020","Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China|Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310228"
132,"NCT04302519","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","COVID-19","Biological: Dental pulp mesenchymal stem cells","Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KT005HB001","March 5, 2020","June 30, 2021","July 30, 2021","March 10, 2020",,"March 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04302519"
133,"NCT04295551","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment","Clinical recovery time","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QF-XYP1990-1","March 14, 2020","July 14, 2020","April 14, 2021","March 4, 2020",,"March 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04295551"
134,"NCT04325646","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","CORSER","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|COVID-19","Other: Human Biological samples","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies","Institut Pasteur","All","5 Years and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-007","March 13, 2020","February 28, 2021","February 28, 2023","March 27, 2020",,"March 31, 2020","CHU Amiens-Picardie, Amiens, France|CHU François Mitterand, Dijon, France|CHU Limoges, Limoges, France|Hôpital de la Croix Rousse, Lyon, France|Hôpitaux de Brabois, Nancy, France|CHR Orléans, Orléans, France|Institut Pasteur, Paris, France|CHU Poitiers, Poitiers, France|Hôpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-Étienne, France|CH de Tourcoing, Tourcoing, France|Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT04325646"
135,"NCT04292964","Prognostic Factors of Patients With COVID-19",,"Completed","No Results Available","SARS-CoV-2|Outcome, Fatal",,"all-cause mortality|Severe state","Chongqing Medical University","All","18 Years and older   (Adult, Older Adult)",,"201","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02-2","March 1, 2020","March 13, 2020","March 13, 2020","March 3, 2020",,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04292964"
136,"NCT04331054","Protective Role of Inhaled Steroids for Covid-19 Infection","INHASCO","Not yet recruiting","No Results Available","Covid-19 Infection|Hospitalization in Respiratory Disease Department","Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice","Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 200394|2020-001306-35","April 2020","July 2020","July 2020","April 2, 2020",,"April 2, 2020","Hôpital Bichat - Service de Pneumologie, Paris, France",,"https://ClinicalTrials.gov/show/NCT04331054"
137,"NCT04335552","Phase 2 Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","SARS-CoV-2","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Duke University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00105339","April 2020","August 1, 2020","August 1, 2020","April 6, 2020",,"April 6, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04335552"
138,"NCT04278963","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19",,"Active, not recruiting","No Results Available","CoVID-19|Chinese Medicine","Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment","Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events","China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","YHQW-V3.0","February 27, 2020","January 2021","January 2021","February 20, 2020",,"March 17, 2020","Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04278963"
139,"NCT04303507","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","COPCOV","Not yet recruiting","No Results Available","COVID19|Coronavirus|Acute Respiratory Illnesses","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses","University of Oxford","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","40000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","VIR20001","April 2020","April 2021","April 2021","March 11, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04303507"
140,"NCT04272710","Prognositc Factors in COVID-19 Patients Complicated With Hypertension",,"Withdrawn","No Results Available","2019-nCoV",,"Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery","Chongqing Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02","January 25, 2020","March 31, 2020","April 30, 2020","February 17, 2020",,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04272710"
141,"NCT04273763","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)",,"Enrolling by invitation","No Results Available","Novel Coronavirus Pneumonia|2019-nCoV","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray","Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality","Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019NCP1.0","February 16, 2020","April 15, 2020","April 30, 2020","February 18, 2020",,"March 23, 2020","The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04273763"
142,"NCT04303299","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial","THDMS-COVID19","Not yet recruiting","No Results Available","Coronavirus Infections|COVID19","Drug: Oral","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Rajavithi Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-DMS-COVID19 study","March 15, 2020","October 31, 2020","November 30, 2020","March 11, 2020",,"March 25, 2020","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04303299"
143,"NCT04331613","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS",,"Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Virus; Pneumonia|Acute Lung Injury","Biological: CAStem","Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9/L)|Alanine aminotransferase (U/L)|Creatinine (umol/L)|Creatine kinase (U/L)|C-reactive protein (mg/L)|Procalcitonin (ng/L)|Lactate (mmol/L)|IL-1beta (pg/mL)|IL-2 (pg/mL)|IL-6 (pg/mL)|IL-8 (pg/mL)","Chinese Academy of Sciences|Beijing YouAn Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChineseASZQ-006","January 27, 2020","December 2020","December 2020","April 2, 2020",,"April 2, 2020","Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China",,"https://ClinicalTrials.gov/show/NCT04331613"
144,"NCT04310865","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",,"Not yet recruiting","No Results Available","COVID-19|Severe Pneumonia|Chinese Medicine","Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment","changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events","Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","YHQW-Severe-V2.0","March 20, 2020","March 30, 2021","June 30, 2021","March 17, 2020",,"March 17, 2020","Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310865"
145,"NCT04324021","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.",,"Recruiting","No Results Available","SARS-CoV-2","Biological: Emapalumab|Biological: Anakinra","Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge","Swedish Orphan Biovitrum","All","30 Years to 79 Years   (Adult, Older Adult)","Phase 2|Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sobi.IMMUNO-101|2020-001167-93","April 2020","July 2020","September 2020","March 27, 2020",,"April 6, 2020","ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04324021"
146,"NCT04319445","Mindfulness During COVID-19",,"Not yet recruiting","No Results Available","Migraine Disorders|Stress|Anxiety","Behavioral: Mindfulness session(s)","Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference","Wake Forest University Health Sciences","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00064587","March 2020","December 2020","December 2020","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04319445"
147,"NCT04319731","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure",,"Not yet recruiting","No Results Available","SARS CoV-2 Infection","Biological: Human Amniotic Fluid","Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131618","March 20, 2020","March 20, 2021","March 20, 2021","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04319731"
148,"NCT04334967","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care",,"Enrolling by invitation","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality","Providence Health & Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute","All","45 Years and older   (Adult, Older Adult)","Phase 4","1250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020000186","March 30, 2020","September 30, 2021","September 30, 2023","April 6, 2020",,"April 6, 2020","Portland Providence Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04334967"
149,"NCT04321928","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","PROACTIVE-19","Not yet recruiting","No Results Available","SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV","Behavioral: Personalized health education|Behavioral: General health education","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care","University of Pecs","All","60 Years and older   (Adult, Older Adult)","Not Applicable","7576","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","IV/2428- 2 /2020/EKU","April 1, 2020","April 21, 2021","August 21, 2021","March 25, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04321928"
150,"NCT04298060","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","STOP-Flu","Not yet recruiting","No Results Available","Influenza Infection|SAD-RV Infection and COVID-19","Drug: DAS181|Drug: Placebo","Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement","Ansun Biopharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAS181-2-07","April 2020","March 2021","September 2022","March 6, 2020",,"April 2, 2020","Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04298060"
151,"NCT04270383","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children",,"Not yet recruiting","No Results Available","2019-nCoV",,"The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial","Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Children’s Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University","All","up to 18 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BCH Lung 012","February 15, 2020","December 31, 2020","December 31, 2020","February 17, 2020",,"February 17, 2020","Beijing Children's Hospital,, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04270383"
152,"NCT04332991","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","ORCHID","Not yet recruiting","No Results Available","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine|Drug: Placebo","COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","510","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PETAL 05 Orchid","April 2020","April 2021","July 2021","April 3, 2020",,"April 3, 2020","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04332991"
153,"NCT04334954","SARS-COV2 Pandemic Serosurvey and Blood Sampling",,"Recruiting","No Results Available","SARS-COV2 Virus",,"Number of people with detectable antibodies to SARS-COV2","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200083|20-I-0083","April 9, 2020","March 31, 2022","March 31, 2022","April 6, 2020",,"April 6, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04334954"
154,"NCT04320511","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",,"Not yet recruiting","No Results Available","SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19","Device: CT-V","Predictive association between CT-V, PBM score and disease progression","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-087","April 2020","March 2021","March 2022","March 25, 2020",,"March 31, 2020","Beaumont Health, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04320511"
155,"NCT04324528","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV","Recruiting","No Results Available","Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate","Dr. Alexander Supady|University Hospital Freiburg","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYCOV","March 27, 2020","September 26, 2020","November 26, 2020","March 27, 2020",,"March 31, 2020","University Clinic Freiburg, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT04324528"
156,"NCT04323878","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","Not yet recruiting","No Results Available","Early CPAP Ventilation in COVID-19 Patients",,"Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EC-COVID-PCS-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 27, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04323878"
157,"NCT04285190","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019|Novel Coronavirus Pneumonia","Drug: T89","The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment","Tasly Pharmaceuticals, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T89-NCP-01","February 26, 2020","June 15, 2020","September 15, 2020","February 26, 2020",,"February 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04285190"
158,"NCT04324606","A Study of a Candidate COVID-19 Vaccine (COV001)",,"Not yet recruiting","No Results Available","Coronavirus","Biological: ChAdOx1 nCoV-19|Biological: MenACWY Placebo","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","510","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COV001","April 2020","May 2021","May 2021","March 27, 2020",,"April 6, 2020","NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04324606"
159,"NCT04325412","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","CAPACITY-COVID","Recruiting","No Results Available","COVID-19; Cardiovascular Diseases",,"The incidence of cardiovascular complications in patients with COVID-19","UMC Utrecht","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-161/C","March 23, 2020","March 23, 2021","June 23, 2021","March 27, 2020",,"March 27, 2020","University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04325412"
160,"NCT04323800","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","CSSC-001","Not yet recruiting","No Results Available","Coronavirus|Convalescence","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Cumulative incidence of composite outcome of disease severity|Anti-SARS-CoV-2 titers|Rates of SARS-CoV-2 PCR positivity|Duration of SARS-CoV-2 PCR positivity|Peak quantity levels of SARS-CoV-2 RNA","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00245634","April 1, 2020","December 31, 2022","January 2023","March 27, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04323800"
161,"NCT04321096","The Impact of Camostat Mesilate on COVID-19 Infection","CamoCO-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Day 30 mortality|Change in NEW(2) score from baseline to day 30|Admission to ICU|Use of invasive mechanical ventilation or ECMO|Duration of supplemental oxygen (days)|Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30","University of Aarhus","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-001200-42","March 31, 2020","December 31, 2020","May 1, 2021","March 25, 2020",,"April 6, 2020","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04321096"
162,"NCT04332380","Convalescent Plasma for Patients With COVID-19: A Pilot Study","CP-COVID-19","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma","Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud","All","18 Years to 60 Years   (Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABN011-1","April 1, 2020","August 31, 2020","December 31, 2020","April 2, 2020",,"April 2, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04332380"
163,"NCT04332666","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","ATCO","Not yet recruiting","No Results Available","Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2","Drug: Angiotensin 1-7|Drug: Placebos","ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings","Erasme University Hospital|Fonds Erasme pour la Recherche Médicale","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P2020/201","March 31, 2020","May 30, 2020","June 15, 2020","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04332666"
164,"NCT04268537","Immunoregulatory Therapy for 2019-nCoV",,"Not yet recruiting","No Results Available","2019 nCoV, PD-1","Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment","lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days","Southeast University, China","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2020YFC0841300-03","February 10, 2020","April 30, 2020","October 31, 2020","February 13, 2020",,"February 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04268537"
165,"NCT04330495","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","Drug: Experimental group|Drug: Control group","Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events","Instituto de Investigación Marqués de Valdecilla","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","EnCOVID-HidroxiCLOROQUINA","April 6, 2020","November 6, 2020","November 6, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330495"
166,"NCT04332835","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","CP-COVID-19","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma|Drug: Hydroxychloroquine|Drug: Azithromycin","Change in Viral Load|Change in Immunoglobulin M COVID-19 Titers|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABN011-2","April 1, 2020","August 31, 2020","December 31, 2020","April 3, 2020",,"April 3, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04332835"
167,"NCT04306705","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","TACOS","Recruiting","No Results Available","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells","Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","WHTJCOVID-19","February 20, 2020","May 30, 2020","June 20, 2020","March 13, 2020",,"March 17, 2020","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04306705"
168,"NCT04334876","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","COVID-Antibody","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit","Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy","Indiana University","All","18 Years and older   (Adult, Older Adult)",,"340","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2003973826","April 1, 2020","November 1, 2020","January 1, 2021","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334876"
169,"NCT04304690","Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","SEROCOV","Recruiting","No Results Available","Sars-CoV2","Other: blood sample","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|"" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome ""","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult","Not Applicable","1000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","APHP200310","March 16, 2020","July 16, 2020","October 16, 2020","March 11, 2020",,"March 19, 2020","Hopital Pitié Salpetrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04304690"
170,"NCT04320472","Acute Encephalopathy in Critically Ill Patients With SARS-Cov-2 Infection","NeuroCOVID19","Recruiting","No Results Available","COVID-19|Encephalopathy|Critically Ill","Other: Follow up","prevalence|Favorable outcome","Ictal Group","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Neuro-COVID-19","March 23, 2020","December 2020","December 2020","March 25, 2020",,"April 1, 2020","Centre Hospitalier de Versailles, Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT04320472"
171,"NCT04312100","Sequential Oxygen Therapy Strategy for Patients With COVID-19","SOTSPC","Recruiting","No Results Available","Coronavirus Disease-2019","Other: oxygen treatment","Incidence of respiratory failure|28 day mortality rate","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SOT-C","February 1, 2020","October 2020","February 2021","March 18, 2020",,"March 18, 2020","Henan Provincial People's Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT04312100"
172,"NCT04252664","Mild/Moderate 2019-nCoV Remdesivir RCT",,"Recruiting","No Results Available","2019-nCoV","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events","Capital Medical University|Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 1","February 12, 2020","April 10, 2020","April 27, 2020","February 5, 2020",,"February 24, 2020","Jin Yin-tan hospital, Wu Han, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04252664"
173,"NCT04313946","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","AI-COVID-Xr","Recruiting","No Results Available","COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","COVID-19 positive X-Rays|COVID-19 negative X-Rays","Professor Adrian Covic|Falcon Trading Iasi|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","0110","March 18, 2020","August 16, 2020","August 18, 2020","March 18, 2020",,"April 2, 2020","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04313946"
174,"NCT04312009","Losartan for Patients With COVID-19 Requiring Hospitalization",,"Not yet recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Sequential Organ Failure Assessment (SOFA) Respiratory Score|28-Day Mortality|90-Day Mortality|Respiratory Failure Requiring Mechanical Ventilation|Number of 28-Day Ventilator-Free Days|Length of Hospital Stay|ICU Admission|ICU Length of Stay|Acute Kidney Injury|Hypotension Requiring Vasopressors|Sequential Organ Failure Assessment (SOFA) Total Score|Severity Assessment|Incidence of Respiratory Failure|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28675","April 2, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"April 3, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04312009"
175,"NCT04315948","Trial of Treatments for COVID-19 in Hospitalized Adults","DisCoVeRy","Recruiting","No Results Available","Corona Virus Infection","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Phase 3","3100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C20-15","March 22, 2020","March 2023","March 2023","March 20, 2020",,"March 25, 2020","CHRU Lille, Lille, France|CHU Nantes, Nantes, France|APHP - Bichat Claude Bernard, Paris, France",,"https://ClinicalTrials.gov/show/NCT04315948"
176,"NCT04311177","Losartan for Patients With COVID-19 Not Requiring Hospitalization",,"Not yet recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Fever Incidence Day 3|Fever Incidence Day 5|Fever Incidence Day 7|Fever Incidence Day 10|Severity of Symptoms upon Hospital Admission","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","516","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28683","April 2, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"April 3, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04311177"
177,"NCT04335032","EPA-FFA to Treat Hospitalised Patients With SARS-CoV-2",,"Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Eicosapentaenoic acid gastro-resistant capsules","Efficacy of EPA-FFA|Increase in oxygen saturation|PaO2/FiO2 >300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction","S.L.A. Pharma AG","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPA-COV-001","April 13, 2020","July 13, 2020","July 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335032"
178,"NCT04252118","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus",,"Recruiting","No Results Available","2019 Novel Coronavirus Pneumonia","Biological: MSCs","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Wuhan Huoshenshan Hospital, Wuhan, China|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020003D","January 27, 2020","December 2020","December 2021","February 5, 2020",,"February 26, 2020","Beijing 302 Military Hospital of China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04252118"
179,"NCT04261426","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: Intravenous Immunoglobulin|Other: Standard care","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events","Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVIG-001","February 10, 2020","April 30, 2020","June 30, 2020","February 7, 2020",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04261426"
180,"NCT04273646","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia|COVID-19","Biological: UC-MSCs|Drug: Placebo","Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202001","February 16, 2020","June 30, 2020","February 15, 2022","February 18, 2020",,"February 21, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04273646"
181,"NCT04332016","COVID-19 Biological Samples Collection","COLCOV19-BX","Recruiting","No Results Available","Infection Viral","Other: biological samples collection","COVID-19 desease description","University Hospital, Bordeaux","All","up to 100 Years   (Child, Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2020/11","April 2, 2020","March 2023","March 2023","April 2, 2020",,"April 3, 2020","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04332016"
182,"NCT04255017","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV","Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200128","February 1, 2020","June 1, 2020","July 1, 2020","February 5, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04255017"
183,"NCT04254874","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV","Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200131","February 1, 2020","June 1, 2020","July 1, 2020","February 5, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04254874"
184,"NCT04275414","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","BEST-CP","Recruiting","No Results Available","Coronavirus Infections","Drug: Bevacizumab Injection","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QLEmer20200214","February 15, 2020","April 2020","May 2020","February 19, 2020",,"April 3, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy",,"https://ClinicalTrials.gov/show/NCT04275414"
185,"NCT04316949","Predictors of Respiratory Failure in SARS-Cov-2 Infection",,"Recruiting","No Results Available","SARS-CoV-2 Pneumonia",,"Respiratory failure|Occurence of bacterial superinfection","University of Bologna","All","18 Years to 99 Years   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PREDI-CO","March 20, 2020","April 30, 2020","May 31, 2020","March 20, 2020",,"March 27, 2020","University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04316949"
186,"NCT04323761","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection",,"Available","No Results Available","SARS-CoV2 Infection","Drug: Remdesivir",,"Gilead Sciences","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"GS-US-540-5821",,,,"March 27, 2020",,"April 6, 2020","Huntington Hospital, Pasadena, California, United States|California Pacific Medical Center, San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Maimonides Medical Center, Brooklyn, New York, United States|New York Presbyterian Hospital, Flushing, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States",,"https://ClinicalTrials.gov/show/NCT04323761"
187,"NCT04261270","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV Pneumonia","Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir","Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery","Tongji Hospital","All","18 Years to 55 Years   (Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ASC09F-CTP-TJ-01","February 1, 2020","May 1, 2020","July 1, 2020","February 7, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04261270"
188,"NCT04332042","TOFAcitinib in SARS-CoV2 Pneumonia",,"Not yet recruiting","No Results Available","SARS-COv2 Related Interstitial Pneumonia","Drug: Tofacitinib","need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events","Università Politecnica delle Marche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOFACoV","April 10, 2020","June 20, 2020","July 10, 2020","April 2, 2020",,"April 2, 2020","Ospedali Riuniti di Ancona, Ancona, Marche, Italy",,"https://ClinicalTrials.gov/show/NCT04332042"
189,"NCT04311697","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","COVID-AIV","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection","Drug: Aviptadil by intravenous infusion + maximal intensive care|Drug: Normal Saline Infusion + Maximal intensive care","Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days","NeuroRx, Inc.|Relief Therapeutics Holding SA|Target Health Inc.|Lavin Consulting, LLC","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","120","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID-AIV","April 2020","August 2020","September 2020","March 17, 2020",,"April 3, 2020","Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Baylor College of Medicine, Houston, Texas, United States|Rambam Health Care Campus, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT04311697"
190,"NCT04316728","Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infections","Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test","Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients","Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VivaDiag-2020","March 2020","September 2020","November 2020","March 20, 2020",,"March 20, 2020","Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04316728"
191,"NCT04327349","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial",,"Enrolling by invitation","No Results Available","Coronavirus Infections","Biological: Convalescent Plasma","Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization","Mazandaran University of Medical Sciences","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1","March 28, 2020","May 20, 2020","September 30, 2020","March 31, 2020",,"March 31, 2020","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04327349"
192,"NCT04328129","Household Transmission Investigation Study for COVID-19 in French Guiana","EPI-COVID-19","Recruiting","No Results Available","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","Procedure: Human biological samples","Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases","Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andrée Rosemon de Cayenne","All","Child, Adult, Older Adult","Not Applicable","450","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2020-009","March 23, 2020","March 23, 2022","March 23, 2022","March 31, 2020",,"March 31, 2020","Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana",,"https://ClinicalTrials.gov/show/NCT04328129"
193,"NCT04329195","ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","ACORES-2","Not yet recruiting","No Results Available","History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge","Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitié-Salpêtrière","All","18 Years and older   (Adult, Older Adult)","Phase 3","554","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200409","April 2020","May 2020","May 2020","April 1, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04329195"
194,"NCT04263402","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia",,"Recruiting","No Results Available","2019-nCoV Severe Pneumonia","Drug: Methylprednisolone","Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200201","February 1, 2020","June 1, 2020","July 1, 2020","February 10, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04263402"
195,"NCT02735707","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","REMAP-CAP","Recruiting","No Results Available","Community-acquired Pneumonia, Influenza, COVID-19","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra","All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization","MJM Bonten|Berry Consultants|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Phase 4","6800","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","April 11, 2016","December 2021","June 2022","April 13, 2016",,"March 30, 2020","Wollongong Hospital, Sidney, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02735707"
196,"NCT04327505","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","COVID-19-HBO","Not yet recruiting","No Results Available","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Cytokine Storm|Infection Viral","Drug: Hyperbaric oxygen","PO2/FiO2 (Safety)|PO2/FiO2 (Efficacy)|Early Warning Score (NEWS) (Safety)|Early Warning Score (NEWS) (Efficacy)|Immunological response (Efficacy)|Mechanical ventilation (Efficacy)|SAE|Serious ADR|AE|Oxygen dose|Pulmonary CT (low-dose CT)|Chest X-ray|Chest ultrasound|Secondary infections|Mortality|ICU free days|ICU mortality|Hospital mortality|Micro RNA plasma (Biomarker)|MicroRNA/RNA PBMC (Explanatory)|Immunological response (Explanatory)|Viral load","Karolinska University Hospital|Karolinska Institutet|University of California, San Diego|Blekinge County Council Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K-2020-2611|2020-001349-37|4-1199/2020","April 25, 2020","October 31, 2021","December 31, 2022","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04327505"
197,"NCT04256395","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","COVID-19","Recruiting","No Results Available","Susceptibility to Viral and Mycobacterial Infection","Other: mobile internet survey on self-test","positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient","Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University","All","Child, Adult, Older Adult",,"300000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RWS-BTCH-002","February 1, 2020","July 31, 2020","July 31, 2020","February 5, 2020",,"February 20, 2020","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04256395"
198,"NCT04325919","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong",,"Recruiting","No Results Available","Coronavirus Infections","Other: No intervention","Clinical|Virological|Microbiological","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"170","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-19 study 2020.076","February 24, 2020","February 28, 2021","June 17, 2021","March 30, 2020",,"March 30, 2020","Prince of Wales Hospital, Sha Tin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04325919"
199,"NCT04324866","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy",,"Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Nasopharyngeal swab","Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions","Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years to 75 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Gisondi 4","April 1, 2020","November 2020","December 2020","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04324866"
200,"NCT04305457","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","NoCovid","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Nitric Oxide","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NOgas mildCOVID-19","March 21, 2020","April 1, 2021","April 1, 2022","March 12, 2020",,"April 3, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04305457"
201,"NCT04324463","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","ACT COVID19","Not yet recruiting","No Results Available","Coronavirus|Severe Acute Respiratory Syndrome","Drug: Azithromycin|Drug: Chloroquine","Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality","Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRI.ACT.COVID19","April 1, 2020","September 30, 2020","December 31, 2020","March 27, 2020",,"March 27, 2020","Hamilton Health Sciences, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04324463"
202,"NCT04320277","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","BARI-COVID","Recruiting","No Results Available","Pharmacological Action","Drug: Baricitinib","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.","Hospital of Prato","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPrato-3","March 16, 2020","April 30, 2020","April 30, 2020","March 24, 2020",,"March 24, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",,"https://ClinicalTrials.gov/show/NCT04320277"
203,"NCT04327570","In-depth Immunological Investigation of COVID-19.","COntAGIouS","Not yet recruiting","No Results Available","Coronavirus Infections","Other: Patient sampling","Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COntAGIouS","March 27, 2020","September 30, 2020","September 30, 2020","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04327570"
204,"NCT04333368","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","STROMA-CoV2","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","APHP200395|2020-001287-28","April 1, 2020","June 30, 2020","May 31, 2021","April 3, 2020",,"April 3, 2020","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04333368"
205,"NCT04325867","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","eCardioCovid19","Recruiting","No Results Available","Angina Pectoris|Acute Coronary Syndrome|Coronary Syndrome|Coronary Artery Disease|Angioplasty|Stent Restenosis|Hypertension|Heart Failure, Systolic|Depression, Anxiety|Covid-19|Isolation, Social","Other: Tele-medicine platform","Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given","Professor Adrian Covic|Medical Sciences Academy - Romania|Victor Babes Clinical Hospital of Infectious Diseases - Bucharest|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GTP0032","March 31, 2020","October 1, 2020","October 1, 2020","March 30, 2020",,"April 1, 2020","Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania",,"https://ClinicalTrials.gov/show/NCT04325867"
206,"NCT04323787","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID19 Registry","VIRUS","Recruiting","No Results Available","Coronavirus","Other: observational","ICU and hospital mortality of COVID-19 patients|30 days mortality","Mayo Clinic","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","20-002610","March 30, 2020","April 30, 2021","April 30, 2021","March 27, 2020",,"April 3, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04323787"
207,"NCT04327401","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","CODEX","Not yet recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Dexamethasone","Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score","Luiz F. L. Reis, Ph.D.|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.|Hospital Sirio-Libanes","All","18 Years and older   (Adult, Older Adult)","Phase 3","290","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","codex_v1.1","April 1, 2020","August 30, 2020","August 30, 2020","March 31, 2020",,"April 1, 2020","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04327401"
208,"NCT04335786","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 Infection Disease",,"Not yet recruiting","No Results Available","Respiratory Distress Syndrome, Adult|SARS-CoV-2","Drug: Valsartan (Diovan)|Drug: Placebo oral tablet","first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury","Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 4","651","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL73547.091.20|2020-001320-34","April 2020","July 2020","August 2021","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335786"
209,"NCT04329533","Effects of Using Mobile App on Perceived Stress During Coronavirus (""COVID 19"") Pandemic",,"Not yet recruiting","No Results Available","Perceived Stress|Anxiety|Sleep Disturbance","Other: ""Calm"" is a mindfulness meditation mobile app","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire","University of Arizona","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pending UA IRB Approval","April 1, 2020","June 30, 2020","July 30, 2020","April 1, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04329533"
210,"NCT04280705","Adaptive COVID-19 Treatment Trial (ACTT)",,"Recruiting","No Results Available","Corona Virus Infection","Other: Placebo|Drug: Remdesivir","Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of infusions|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Ventilator/extracorporeal membrane oxygenation (ECMO) free days","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","440","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006","February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",,"April 6, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health Sciences Center, College of Public Health- Epidemiology, Gainesville, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04280705"
211,"NCT04279197","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu",,"Recruiting","No Results Available","Pulmonary Fibrosis Due to 2019-nCoV","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo","High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index","ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People’s Hospital|Tongji Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Fzhy-ncp-2","February 15, 2020","December 2022","December 2022","February 21, 2020",,"February 21, 2020","Shuguang Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04279197"
212,"NCT04284046","CT Scores Predict Mortality in 2019-nCoV Pneumonia",,"Completed","No Results Available","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Other: CT score","7-day mortality","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","Child, Adult, Older Adult",,"39","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CT2019-nCoV","January 31, 2020","February 18, 2020","February 18, 2020","February 25, 2020",,"February 25, 2020","Wuhan third hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04284046"
213,"NCT04321174","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","CORIPREV-LR","Not yet recruiting","No Results Available","Coronavirus Infections|Post-exposure Prophylaxis","Drug: Lopinavir/ritonavir","Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life","Darrell Tan|St. Michael's Hospital, Toronto","All","18 Months and older   (Child, Adult, Older Adult)","Phase 3","1220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CORIPREV-1","March 30, 2020","March 31, 2021","March 31, 2022","March 25, 2020",,"March 25, 2020","Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04321174"
214,"NCT04318314","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID19-HCW","Recruiting","No Results Available","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Diagnostic Test: COPAN swabbing and blood sample collection","Seroconversion to SARS-CoV-2 positivity","University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130852","March 18, 2020","December 31, 2020","December 31, 2021","March 23, 2020",,"March 26, 2020","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04318314"
215,"NCT04322487","Simple, Safe, Same: Lung Ultrasound for COVID-19","LUSCOVID19","Not yet recruiting","No Results Available","Coronavirus|Epidemic Disease|Pneumonia, Viral","Diagnostic Test: Lung ultrasound","Lung ultrasound grading system for COVID-19 pneumonia","Catholic University of the Sacred Heart|Valle del Serchio General Hospital, Lucca, Italy|University of Trento, Trento, Italy|Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy|Bresciamed, Brescia, Italy|118 USL Nordovest Toscana, Lucca, Italy|General Hospital, Voghera, Italy|Lodi General Hospital, Lodi, Italy","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0013226/20","April 1, 2020","December 31, 2020","January 15, 2021","March 26, 2020",,"March 27, 2020","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy",,"https://ClinicalTrials.gov/show/NCT04322487"
216,"NCT04323592","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","MP-C19","Recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human","Drug: Methylprednisolone|Other: standard care","Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation","University of Trieste","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","104","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-19 023_2020","March 23, 2020","May 20, 2020","May 30, 2020","March 26, 2020",,"March 27, 2020","Marco Confalonieri, Trieste, TS, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04323592"
217,"NCT04335747","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis","Other: COVID-19 infection","Disease activity|Immune modulating treatments|Biomarkers","Salome Kristensen|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"333","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200401","April 8, 2020","August 1, 2021","September 1, 2021","April 6, 2020",,"April 6, 2020","Aalborg University Hospital, Aalborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04335747"
218,"NCT04335188","COVID-19 Registry Rhineland-Palatinate (Germany)",,"Not yet recruiting","No Results Available","COVID","Other: Prospective oberservational registry","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","IHF GmbH - Institut für Herzinfarktforschung|Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","All","Child, Adult, Older Adult",,"4000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19 Registry","April 3, 2020","July 31, 2021","September 30, 2021","April 6, 2020",,"April 6, 2020","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany",,"https://ClinicalTrials.gov/show/NCT04335188"
219,"NCT04335773","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",,"Not yet recruiting","No Results Available","Pediatric Respiratory Diseases|COVID|Fatigue Post Viral",,"Risk Factors|Immunulogical mechanisms|Long term outcome","University Hospital, Akershus|St. Olavs Hospital|Helse Stavanger HF|Haukeland University Hospital|University Hospital of North Norway|Alesund Hospital|Norwegian Institute of Public Health|The University of New South Wales|University of Bristol|Sykehuset Ostfold|Nordlandssykehuset HF|Vestre Viken Hospital Trust|Helse Fonna|Levanger Hospital|Oslo University Hospital|Sykehuset Innlandet HF","All","up to 18 Years   (Child, Adult)",,"350","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20/03794","April 1, 2020","December 31, 2030","December 31, 2030","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335773"
220,"NCT04334629","LIBA Trial in COVID-19","LIBA","Not yet recruiting","No Results Available","Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Ibuprofen","Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days","King's College London|Guy's & St Thomas NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","282009","April 6, 2020","August 5, 2020","November 5, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334629"
221,"NCT04330300","Coronavirus ACEi/ARB Investigation","CORONACION","Recruiting","No Results Available","Hypertension|COVID-19","Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring","National University of Ireland, Galway, Ireland","All","60 Years and older   (Adult, Older Adult)","Phase 4","2414","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","C.A. 2348","March 30, 2020","January 31, 2021","March 1, 2021","April 1, 2020",,"April 2, 2020","University Hospital Galway, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT04330300"
222,"NCT04322565","Colchicine Efficacy in COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Colchicine","Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical venhtilation|Hospitalization|Time from death|Negativization COVID 19|Fever","Lucio Manenti|Azienda Ospedaliero-Universitaria di Parma","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLCOVID01","April 1, 2020","May 30, 2020","June 30, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322565"
223,"NCT04264858","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients",,"Not yet recruiting","No Results Available","2019-nCoV|Immunoglobulin of Cured Patients","Drug: Immunoglobulin of cured patients|Drug: γ-Globulin","Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WuhanUH-2019 nCoV-Ig","March 17, 2020","April 30, 2020","May 31, 2020","February 11, 2020",,"March 17, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04264858"
224,"NCT04321811","Behavior, Environment And Treatments for Covid-19","BEAT19","Recruiting","No Results Available","Coronavirus","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery","xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud","All","18 Years and older   (Adult, Older Adult)",,"100000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XC-PCOR-COVID19","March 21, 2020","March 20, 2021","March 20, 2022","March 25, 2020",,"April 2, 2020","BEAT19.org, San Francisco, California, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04321811"
225,"NCT04326452","Treating COVID-19 With a Bidirectional Oxygenation Valve",,"Recruiting","No Results Available","Coronavirus Infection","Device: bidirectional oxygenation mouthpiece","Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide","TMC HealthCare|PEEP Medical, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19PEEP2020|GO2 PEEP Study","March 27, 2020","May 1, 2020","June 1, 2020","March 30, 2020",,"April 1, 2020","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04326452"
226,"NCT04335162","Cardiovascular Complications and COVID-19 (CovCardioVasc)","CovCardioVasc","Recruiting","No Results Available","COVID|Acute Coronary Syndrome|Myocardial Infarction|Myocarditis|Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism",,"Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid19","February 28, 2020","August 28, 2020","August 28, 2020","April 6, 2020",,"April 6, 2020","CHU de Nice, Nice, France|Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04335162"
227,"NCT04312243","NO Prevention of COVID-19 for Healthcare Providers","NOpreventCOVID","Not yet recruiting","No Results Available","Coronavirus Infections|Healthcare Associated Infection","Drug: Inhaled nitric oxide gas","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Massachusetts General Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","470","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NOpreCOVID-19","April 2, 2020","March 20, 2021","March 20, 2022","March 18, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04312243"
228,"NCT04321616","The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2",,"Not yet recruiting","No Results Available","SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction","Oslo University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","118684","March 26, 2020","August 2020","November 2020","March 25, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04321616"
229,"NCT04335279","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","SPIN-CHAT","Not yet recruiting","No Results Available","Scleroderma|Scleroderma, Systemic|Systemic Sclerosis","Other: SPIN-CHAT Program","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Stress: Perceived Stress Scale (PSS)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Frequency of social interactions|Adverse Effects","Lady Davis Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SPIN-CHAT-001","April 15, 2020","June 3, 2020","June 3, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335279"
230,"NCT04331886","An Observational Study of Patients With Coronavirus Disease 2019","COVID-19","Not yet recruiting","No Results Available","COVID-19|Coronavirus",,"Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response","Target PharmaSolutions, Inc.","All","Child, Adult, Older Adult",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","TARGET-COVID-19","April 2020","March 2021","March 2021","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331886"
231,"NCT04293887","Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients",,"Not yet recruiting","No Results Available","COVID-19|Recombinant Human Interferon α1β","Drug: Recombinant human interferon α1β","The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","328","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Zhaojp","March 1, 2020","May 30, 2020","June 30, 2020","March 3, 2020",,"March 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04293887"
232,"NCT04306055","Blood Donor Recruitment During Epidemic of COVID-19",,"Not yet recruiting","No Results Available","Blood Donation","Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information","Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks","Guangzhou Blood Center","All","18 Years to 60 Years   (Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Blood donor recruitment","March 12, 2020","March 19, 2020","April 9, 2020","March 12, 2020",,"March 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04306055"
233,"NCT04329546","Understanding COVID",,"Recruiting","No Results Available","SARS-CoV-2 Viral Kinetics and Host Immune Responses","Other: NA (no intervention)","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","University Hospital, Geneva|University of Geneva, Switzerland","All","Child, Adult, Older Adult",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00516","March 27, 2020","January 31, 2022","March 31, 2022","April 1, 2020",,"April 1, 2020","University Hospitals of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04329546"
234,"NCT04320732","Risk Factors for Community- and Workplace Transmission of COVID-19",,"Recruiting","No Results Available","Coronavirus","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Rate of COVID-19 infection","Oslo University Hospital|Age Labs AS","All","18 Years and older   (Adult, Older Adult)",,"50000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","REK-124170","March 27, 2020","March 27, 2022","March 20, 2030","March 25, 2020",,"March 31, 2020","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04320732"
235,"NCT04333654","Hydroxychloroquine in Outpatient Adults With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16855|2020-001269-35|U1111-1249-6168","March 31, 2020","May 2020","May 2020","April 3, 2020",,"April 3, 2020","Investigational site number 8401001, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04333654"
236,"NCT04296643","Medical Masks vs N95 Respirators for COVID-19",,"Not yet recruiting","No Results Available","Coronavirus|N95|Medical Mask","Device: Medical Mask|Device: N95 respirator","RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death","McMaster University|Vancouver Coastal Health|University of Alberta|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","576","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","20006014","April 1, 2020","December 1, 2020","January 1, 2021","March 5, 2020",,"March 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04296643"
237,"NCT04319016","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","COVID-preg","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","Federico II University","Female","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Other","145/20","January 1, 2020","April 30, 2020","May 1, 2020","March 24, 2020",,"April 1, 2020","Gabriele Saccone, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04319016"
238,"NCT04302688","Accurate Classification System for Patients With COVID-19 Pneumonitis",,"Completed","No Results Available","Pneumonitis",,"survival status","Renmin Hospital of Wuhan University","All","Child, Adult, Older Adult",,"669","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","COVID-19 WU1","December 10, 2019","February 10, 2020","March 4, 2020","March 10, 2020",,"March 10, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04302688"
239,"NCT04279899","The Investigation of the Neonates With or With Risk of COVID-19",,"Recruiting","No Results Available","Neonatal Infection|Perinatal Problems|Infectious Disease",,"The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19","Children's Hospital of Fudan University","All","up to 28 Days   (Child)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHFudanU_NNICU14","February 1, 2020","November 30, 2020","December 31, 2020","February 21, 2020",,"February 21, 2020","Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04279899"
240,"NCT04290871","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","NOSARSCOVID","Withdrawn","No Results Available","Coronavirus|SARS (Severe Acute Respiratory Syndrome)","Drug: Nitric Oxide Gas","SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air","Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 23, 2020","March 1, 2021","March 1, 2022","March 2, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04290871"
241,"NCT04328454","Clinical Characteristics and Prognostic Factors of Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HBCBH-IEC-2020-101","January 30, 2020","April 2, 2020","April 15, 2020","March 31, 2020",,"March 31, 2020","Shanghai 10th People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04328454"
242,"NCT04316884","Mechanisms for Organ Dysfunction in Covid-19","UMODCOVID19","Recruiting","No Results Available","COVID-19|Organ Dysfunction Syndrome Sepsis|Organ Dysfunction Syndrome, Multiple|Septic Shock|Acute Kidney Injury|Acute Respiratory Distress Syndrome",,"Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score","Uppsala University","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPN 2017/043 Covid19","March 12, 2020","December 31, 2020","December 31, 2021","March 20, 2020",,"March 20, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04316884"
243,"NCT04320238","Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff",,"Recruiting","No Results Available","2019 Novel Coronavirus Infection","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect","Shanghai Jiao Tong University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2944","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Interferon_prophylaxis","January 21, 2020","May 2020","June 2020","March 24, 2020",,"March 31, 2020","Taihe Hospital, Shiyan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04320238"
244,"NCT04334928","Clinical Trial for the Prevention of SARS-CoV-2Infection in Healthcare Personnel (EPICOS)","EPICOS","Active, not recruiting","No Results Available","Coronavirus Infection","Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days","Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","4000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PrEP COVID-19","April 1, 2020","June 30, 2020","July 31, 2020","April 6, 2020",,"April 6, 2020","Hospital Universitario Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04334928"
245,"NCT04327388","Sarilumab COVID-19",,"Recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab SAR153191|Drug: Placebo","Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner|Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale|Phase 2: The time to improvement in oxygenation|Phase 2: Mean change in 7-point ordinal scale from baseline to Day 15|Phase 2: Clinical status using the 7-point ordinal scale at Day 15|Phase 2: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3 : Time to resolution of fever|Phase 2 and 3 : Time to improvement in oxygenation|Phase 2 and 3: Time to resolution of fever and improvement in oxygenation|Phase 2 and 3:Time to change in NEWS2 from baseline|Phase 2 and 3: Time to NEWS2 of <2 and maintained for 24 hours|Phase 2 and 3: Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2|Phase 2 and 3:Days with fever|Phase 2 and 3: Alive off supplemental oxygen at day 29|Phase 2 and 3: Days of resting respiratory rate >24 breaths/min|Phase 2 and 3:Days of hypoxemia|Phase 2 and 3: Days of supplemental oxygen use|Phase 2 and 3: Time to saturation ≥94% on room air|Phase 2 and 3: Ventilator free days in the first 28 days (to day 29)|Phase 2 and 3: The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Phase 2 and 3: Proportion of patients requiring rescue medication during the 28-day period|Phase 2 and 3: The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Phase 2 and 3: Days of hospitalization among survivors|Phase 2 and 3: Incidence of death|Phase 3: Mean change in the 7-point ordinal scale from baseline to days 3, 5, 8, 11, 15, and 29 (or until discharge)|Phase 3: Clinical status using the 7-point ordinal scale at days 3, 5, 8, 11,15, and 29|Phase 3: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3: Incidence of serious adverse events|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|Phase 2 and 3: The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16844|U1111-1249-6021","March 28, 2020","July 30, 2020","June 2021","March 31, 2020",,"April 2, 2020","2500001, Bordeaux Cedex, France",,"https://ClinicalTrials.gov/show/NCT04327388"
246,"NCT04325906","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS",,"Not yet recruiting","No Results Available","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Treatment failure|Intubation rate|Efficacy of PP","Rush University Medical Center|Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-HFNC+PP","April 6, 2020","May 31, 2020","June 30, 2020","March 30, 2020",,"April 3, 2020","Rush University Medical Center, Chicago, Illinois, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04325906"
247,"NCT03808922","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study",,"Recruiting","No Results Available","Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)","Ansun Biopharma, Inc.","All","Child, Adult, Older Adult","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAS181-3-01|2018-004318-16","May 23, 2019","April 30, 2021","December 28, 2021","January 18, 2019",,"April 2, 2020","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03808922"
248,"NCT04325893","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","HYCOVID","Not yet recruiting","No Results Available","Coronavirus","Drug: Hydroxychloroquine|Drug: Placebo","Death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|All-cause mortality at day 14|All-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|All-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|All-cause mortality at day 14 in patients aged 75 and older","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Phase 3","1300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","49RC20_0071","April 2020","September 2020","September 2020","March 30, 2020",,"April 6, 2020","CH Agen, Agen, France|CHU Amiens, Amiens, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|APHP Henri Mondor, Créteil, France|CHU Dijon, Dijon, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT04325893"
249,"NCT04292340","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19",,"Recruiting","No Results Available","Coronavirus",,"The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult",,"15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Anti-SARS-CoV-2","February 1, 2020","July 31, 2020","December 31, 2020","March 3, 2020",,"March 3, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04292340"
250,"NCT04326114","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19",,"Not yet recruiting","No Results Available","Disease, Infectious|Respiratory Disease|Safety Issues|Effectiveness","Device: Inspiratory training device|Device: Expiratory training device","COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects","Universidad Complutense de Madrid","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Covid_ISCIII 20/265-E_BS","April 26, 2020","September 26, 2020","October 12, 2020","March 30, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04326114"
251,"NCT04325048","Clinical Evaluation of Cordio Application in Adult COVID19 Virus Positive Patients",,"Not yet recruiting","No Results Available","Coronavirus Infection","Device: Cordio App","Voice anaysis","Cordio Medical","All","18 Years and older   (Adult, Older Adult)",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV001","April 2020","June 2021","September 2021","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04325048"
252,"NCT04324047","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","CORIMUNO-19","Recruiting","No Results Available","Corona Virus Infection",,"Survival|WHO progression scale COVID 19","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200375|2020-001246-18","March 27, 2020","March 27, 2021","December 31, 2021","March 27, 2020",,"April 1, 2020","Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT04324047"
253,"NCT04315870","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","I-COVID","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","Federico II University","Female","18 Years to 50 Years   (Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Other","5/20","January 1, 2020","April 20, 2020","April 30, 2020","March 20, 2020",,"March 20, 2020","University of Naples Federico II, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04315870"
254,"NCT04326036","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","GARM-COVID19","Enrolling by invitation","No Results Available","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry","Healeon Medical Inc|Robert W. Alexander, MD","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","10","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GARM COVID19","March 25, 2020","November 1, 2021","December 31, 2021","March 30, 2020",,"March 31, 2020","Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States",,"https://ClinicalTrials.gov/show/NCT04326036"
255,"NCT04332094","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","Recruiting","No Results Available","COVID","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-COV-2020-23","April 2, 2020","September 2020","October 2020","April 2, 2020",,"April 6, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04332094"
256,"NCT04322396","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","ProPAC-COVID","Not yet recruiting","No Results Available","Virus Diseases|Infection Viral","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","All","Child, Adult, Older Adult","Phase 4","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KronLungesyg_COVID_19_protokol","April 1, 2020","October 31, 2020","March 31, 2021","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322396"
257,"NCT04274322","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool",,"Not yet recruiting","No Results Available","Critically Ill|Coronavirus Infections","Other: Nutrition support","28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation","Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV_NUTRIC","February 2020","May 2020","July 2020","February 18, 2020",,"February 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04274322"
258,"NCT04324073","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","CORIMUNO-SARI","Recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab","Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale <=7 at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-2","March 27, 2020","March 27, 2021","December 31, 2021","March 27, 2020",,"April 1, 2020","Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04324073"
259,"NCT04331808","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)","CORIMUNO-TOC","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Tocilizumab","Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale <=7 at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-1","March 31, 2020","March 31, 2021","December 31, 2021","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331808"
260,"NCT04321278","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)",,"Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death","Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|Cristália Produtos Químicos Farmacêuticos Ltda.","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30155020.5.1001.0071","March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",,"April 1, 2020","Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|AMICO Saude LTDA, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04321278"
261,"NCT04260594","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: Arbidol|Other: basic treatment","Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count","Jieming QU|Ruijin Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Abdrcspc202001","February 7, 2020","July 1, 2020","December 30, 2020","February 7, 2020",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04260594"
262,"NCT04314232","Mechanisms to Morbidity and Mortality for Covid-19","COVID MECH","Not yet recruiting","No Results Available","Coronavirus|SARS",,"Change in viral expression in association to organspecific biomarkers","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","117589","March 23, 2020","December 31, 2021","December 31, 2021","March 19, 2020",,"March 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04314232"
263,"NCT04330261","Clinical Characteristics and Outcomes of Pediatric COVID-19","PERN-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","Other: Exposure (not intervention) - SARS-CoV-2 infection","Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies","University of Calgary","All","up to 18 Years   (Child, Adult)",,"12500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REB18-0107_MOD9","March 18, 2020","March 17, 2021","March 17, 2022","April 1, 2020",,"April 1, 2020","University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04330261"
264,"NCT04326426","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection",,"Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Tradipitant|Drug: Placebo","Proportion of participants with normalization of fever and oxygen saturation by day 14|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough","Vanda Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VLY-686-3501","April 1, 2020","August 1, 2020","August 31, 2020","March 30, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04326426"
265,"NCT04327180","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","PREDICT","Recruiting","No Results Available","Infection Viral|Coronavirus|ARDS|Pneumonia",,"Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_20|2020-A00763-36","March 30, 2020","September 2021","September 2021","March 30, 2020",,"April 6, 2020","Hôpital Roger Salengro, ICU, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04327180"
266,"NCT04291729","Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection",,"Completed","No Results Available","2019-nCoV Pneumonia","Drug: Ganovo+ritonavir+/-Interferon nebulization","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC-CTP-NC-01","February 17, 2020","March 19, 2020","March 19, 2020","March 2, 2020",,"March 24, 2020","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China",,"https://ClinicalTrials.gov/show/NCT04291729"
267,"NCT04334434","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)",,"Not yet recruiting","No Results Available","Telerehabilitation","Other: Telerehabilitation","Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly","Kubra Koce, MSc PT|Istanbul University-Cerrahpasa","All","65 Years and older   (Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","002","April 1, 2020","June 1, 2020","July 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334434"
268,"NCT04290858","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","NoCovid","Withdrawn","No Results Available","Coronavirus Infections|Pneumonia, Viral|Dyspnea","Drug: Nitric Oxide","Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery","Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19 NOgas mild","March 1, 2020","March 1, 2021","February 1, 2022","March 2, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04290858"
269,"NCT04257656","Severe 2019-nCoV Remdesivir RCT",,"Recruiting","No Results Available","2019-nCov|Remdesivir","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events","Capital Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 3","453","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 2","February 6, 2020","April 3, 2020","May 1, 2020","February 6, 2020",,"February 24, 2020","Bin Cao, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04257656"
270,"NCT04288713","Eculizumab (Soliris) in Covid-19 Infected Patients","SOLID-C19","Available","No Results Available","Coronavirus","Drug: Eculizumab",,"Hudson Medical","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Individual Patients|Treatment IND/Protocol",,"COVID19",,,,"February 28, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04288713"
271,"NCT04318366","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","COVID-BioB","Recruiting","No Results Available","Coronavirus Infections","Other: Observational Study","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Università Vita-Salute San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-BioB/OSR","March 19, 2020","March 19, 2022","March 19, 2022","March 24, 2020",,"March 31, 2020","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy",,"https://ClinicalTrials.gov/show/NCT04318366"
272,"NCT04320953","Non-contact Endoscopy at Covid-19 Outbreak",,"Completed","No Results Available","Gastrointestinal Disease|Infectious Disease","Device: Non-contact MCE system","Technical success|Clinical success|Adverse events","Changhai Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ncMCE1","March 16, 2020","March 16, 2020","March 16, 2020","March 25, 2020",,"March 25, 2020","Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04320953"
273,"NCT04308187","Influence of the COvid-19 Epidemic on STRESS","COVISTRESS","Not yet recruiting","No Results Available","Stress, Psychological",,"Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits","University Hospital, Clermont-Ferrand|Faculty of Medicine, Clermont-Ferrand, France|UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France|Wittyfit, Paris, France","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020 COVISTRESS","March 11, 2020","March 2022","March 2022","March 13, 2020",,"March 13, 2020","University Hospital, Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT04308187"
274,"NCT04306393","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","NOSARSCOVID","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Drug: Nitric Oxide Gas","Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 21, 2020","March 21, 2021","March 21, 2022","March 12, 2020",,"March 24, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04306393"
275,"NCT04322344","Escin in Patients With Covid-19 Infection","add-on-COV2","Recruiting","No Results Available","Coronavirus Infections","Drug: Escin|Drug: standard therapy","Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico ""Mater Domini""","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","covid-19 add-on therapy","March 23, 2020","June 30, 2020","August 30, 2020","March 26, 2020",,"March 27, 2020","Luca Gallelli, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04322344"
276,"NCT04322773","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","TOCIVID","Not yet recruiting","No Results Available","Corona Virus Disease","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care","Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events","Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APPI2-CV-2020-01","April 4, 2020","June 1, 2021","June 1, 2021","March 26, 2020",,"April 3, 2020","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04322773"
277,"NCT04324684","Prognostic Factors Keeping Track for Covid19 Pneumonia","NIKE_C19","Recruiting","No Results Available","Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease",,"rate of recovery|time to improvement|efficacy of treatments|organ failure","Catholic University of the Sacred Heart","All","18 Years to 100 Years   (Adult, Older Adult)",,"198","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20202503","March 31, 2020","May 31, 2020","June 15, 2020","March 27, 2020",,"April 2, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04324684"
278,"NCT04322786","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?",,"Active, not recruiting","No Results Available","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","Drug: ACE inhibitor","Incidence of influenza","University College, London","All","18 Years and older   (Adult, Older Adult)",,"1302508","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ISAC17_205R","January 1, 1998","May 31, 2016","March 31, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322786"
279,"NCT04333849","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49","TOVID-49","Recruiting","No Results Available","Old Age, Usability, Visio Telephony, Confinement, Covid-19",,"To identify the preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|To assess the proportion of elderly people with loss of functional independence to communicate with their relatives.|To assess the level of satisfaction of patients who have benefited from a telephone call.|To assess the level of satisfaction of patients who have benefited from a videophone call.|To assess the satisfaction levels of older people according to the means of communication used.|To assess the impact of age on the preferred means of communication.","University Hospital, Angers","All","70 Years and older   (Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/29","March 27, 2020","September 2020","September 2020","April 3, 2020",,"April 3, 2020","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04333849"
280,"NCT04327479","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection",,"Recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|SARS","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","All-cause mortality|30-day mortality|Major adverse cardiovascular events","University Hospital, Essen","All","18 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-9213-BO","March 26, 2020","March 25, 2026","March 25, 2026","March 31, 2020",,"March 31, 2020","University Hospital Essen, Essen, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT04327479"
281,"NCT04322123","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus","Coalition-I","Not yet recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction","Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS","All","18 Years and older   (Adult, Older Adult)","Phase 3","630","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Brazil COVID Coalition I Trial","April 6, 2020","August 30, 2020","August 30, 2020","March 26, 2020",,"March 26, 2020","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital da Luz - Amico Saúde LTDA, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP - Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04322123"
282,"NCT04305574","Social Media Use During COVID-19",,"Recruiting","No Results Available","Coronavirus|Depression|Anxiety|Stress","Behavioral: Use of social media during COVID-19","Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic","Jean Liu|Yale-NUS College","All","21 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020-CERC-001","March 8, 2020","May 31, 2020","May 31, 2020","March 12, 2020",,"March 17, 2020","Yale-NUS College, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04305574"
283,"NCT04326387","Evaluation of Novel Diagnostic Tests for 2019-nCOV","COVIDx","Not yet recruiting","No Results Available","Acute Disease|Coronavirus|Respiratory Viral Infection","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDx","April 8, 2020","April 7, 2021","October 7, 2021","March 30, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04326387"
284,"NCT04279795","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations",,"Recruiting","No Results Available","Coronavirus",,"Positive rate of 2019 Novel Coronavirus RNA|Survival rate","Third Affiliated Hospital, Sun Yat-Sen University","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PL11","January 20, 2020","January 31, 2021","February 28, 2021","February 21, 2020",,"February 21, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04279795"
285,"NCT04279782","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection",,"Recruiting","No Results Available","Coronavirus","Other: Comprehensive treatment","Survival rate|Chest computed tomography|Recovery Time|Depression evaluation","Third Affiliated Hospital, Sun Yat-Sen University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XWX3","January 20, 2020","January 31, 2021","February 28, 2021","February 21, 2020",,"February 24, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04279782"
286,"NCT04292327","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","2019-nCoV","Active, not recruiting","No Results Available","Pneumonia Caused by Human Coronavirus",,"Mortality|The time interval of Nucleic acid detection become negative","Fujian Provincial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","KY-2020-24.01","January 1, 2020","April 30, 2020","July 31, 2020","March 3, 2020",,"March 3, 2020","Fujian Provincial Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04292327"
287,"NCT04269525","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia",,"Recruiting","No Results Available","Pneumonia, Viral|Pneumonia, Ventilator-Associated","Biological: UC-MSCs","Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)","ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020002","February 6, 2020","April 30, 2020","September 30, 2020","February 13, 2020",,"February 17, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04269525"
288,"NCT04261907","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group","The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal","First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC09F-CTP-ZY-01","February 7, 2020","May 31, 2020","June 30, 2020","February 10, 2020",,"February 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04261907"
289,"NCT04325672","Convalescent Plasma to Limit Coronavirus Associated Complications",,"Not yet recruiting","No Results Available","Coronavirus","Biological: Convalescent Plasma","RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20-002864","April 1, 2020","December 31, 2022","December 31, 2022","March 27, 2020",,"March 27, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04325672"
290,"NCT04326075","Early CPAP in COVID Patients With Respiratory Failure.","EC-COVID-RCT","Not yet recruiting","No Results Available","CPAP Ventilation|COVID-19|Emergency Departments","Device: CPAP treatment","Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC-COVID-RCT-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 30, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04326075"
291,"NCT04323839","PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","PRIORITY","Recruiting","No Results Available","Pregnancy|Coronavirus|COVID-19","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19","University of California, San Francisco|University of California, Los Angeles","Female","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-30410","March 20, 2020","March 31, 2024","March 31, 2024","March 27, 2020",,"March 27, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04323839"
292,"NCT04061382","Sero-epidemiological Survey of England in 2019/2020","STORY","Recruiting","No Results Available","Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19","Procedure: venepuncture","Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection","University of Oxford","All","up to 24 Years   (Child, Adult)",,"2300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ID 263097","October 15, 2019","April 30, 2020","November 30, 2020","August 19, 2019",,"March 24, 2020","Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04061382"
293,"NCT04264533","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia",,"Recruiting","No Results Available","Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated","Drug: VC|Drug: Sterile Water for Injection","Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores","ZhiYong Peng|Zhongnan Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2020001","February 14, 2020","September 30, 2020","September 30, 2020","February 11, 2020",,"March 10, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04264533"
294,"NCT04302766","Expanded Access Remdesivir (RDV; GS-5734™)",,"Available","No Results Available","Coronavirus Disease 2019","Drug: Remdesivir",,"U.S. Army Medical Research and Development Command","All","Child, Adult, Older Adult",,,"U.S. Fed","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"S-20-01",,,,"March 10, 2020",,"March 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04302766"
295,"NCT04323527","Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","CloroCOVID19","Recruiting","No Results Available","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Drug: Chloroquine diphosphate","Absolute mortality at day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vinícius Guimarães de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mourão|Ludmila Abrahão Hajjar|Jorge Souza Mendonça","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAAE: 30152620.1.0000.0005","March 23, 2020","August 31, 2020","August 31, 2020","March 26, 2020",,"March 30, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,"https://ClinicalTrials.gov/show/NCT04323527"
296,"NCT04275388","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QF-XYP2001-1","February 14, 2020","May 14, 2020","December 14, 2021","February 19, 2020",,"February 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04275388"
297,"NCT04245631","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",,"Recruiting","No Results Available","New Coronavirus","Diagnostic Test: Recombinase aided amplification (RAA) assay","Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%","Beijing Ditan Hospital","All","1 Year to 90 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DTXY022","January 1, 2020","December 31, 2020","December 31, 2020","January 29, 2020",,"January 29, 2020","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04245631"
298,"NCT04283461","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection",,"Recruiting","No Results Available","Corona Virus Infection|Immunisations","Biological: mRNA-1273","Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 55 Years   (Adult)","Phase 1","45","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-0003|1UM1AI148373-01","March 3, 2020","June 1, 2021","June 1, 2021","February 25, 2020",,"March 30, 2020","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04283461"
299,"NCT04331106","Survey of the Anxiety Associated With the SARS-CoV-2 Pandemic","CORA","Recruiting","No Results Available","Anxiety Related to the SARS-CoV-19 Pandemic","Diagnostic Test: Online Questionnaire","Characteristics of SARS-CoV-19-related anxiety|SARS-CoV-19-related anxiety symptoms|Self-efficacy and coping with SARS-CoV-19|Consequences of SARS-CoV-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of SARS-CoV-19-related anxiety|Change in SARS-CoV-19-related anxiety symptoms","Charite University, Berlin, Germany","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA1/071/20","March 27, 2020","September 2020","September 2021","April 2, 2020",,"April 2, 2020","Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04331106"
300,"NCT03331445","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","NONTM","Active, not recruiting","No Results Available","Respiratory Tract Infections|Corona Virus Infection","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score","University of British Columbia|Mallinckrodt","All","14 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTM-CTP-01: H17-02107","October 24, 2017","December 31, 2020","March 31, 2021","November 6, 2017",,"March 31, 2020","Diamond Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03331445"
301,"NCT04324736","""Coronavirus SARS-CoV2 and Diabetes Outcomes""","CORONADO","Recruiting","No Results Available","Coronavirus|Diabetes","Other: no interventional study","Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19","Nantes University Hospital","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Other","RC20_0148","March 31, 2020","April 10, 2020","May 8, 2020","March 27, 2020",,"April 6, 2020","CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04324736"
302,"NCT04322682","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Colchicine|Drug: Placebo oral tablet","Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation","Montreal Heart Institute|DACIMA Software","All","40 Years and older   (Adult, Older Adult)","Phase 3","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MHIPS-2020-001","March 23, 2020","September 2020","September 2020","March 26, 2020",,"March 27, 2020","Montreal Heart Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04322682"
303,"NCT04255940","2019-nCoV Outbreak and Cardiovascular Diseases",,"Recruiting","No Results Available","Cardiovascular Death; Major Adverse Cardiovascular Events",,"Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety","Qilu Hospital of Shandong University","All","Child, Adult, Older Adult",,"12000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2019nCoV-CVD","January 20, 2020","April 30, 2020","April 30, 2020","February 5, 2020",,"February 5, 2020","Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04255940"
304,"NCT04315480","Tocilizumab for SARS-CoV2 Severe Pneumonitis",,"Active, not recruiting","No Results Available","SARS Pneumonia","Drug: Tocilizumab","arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death","Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCICOV-1","March 12, 2020","April 9, 2020","May 2020","March 19, 2020",,"April 6, 2020","Università Politecnica delle Marche, Ancona, AN, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04315480"
305,"NCT04322513","Biomarkers for Identification of SARS-COV-2 Infection","B-DT-COV2","Recruiting","No Results Available","Coronavirus","Diagnostic Test: Biomarkers expression","Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico ""Mater Domini""","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"110","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","covid-19 biomarkers","March 24, 2020","June 30, 2020","August 30, 2020","March 26, 2020",,"March 27, 2020","Luca Gallelli, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04322513"
306,"NCT04290780","Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","NOSO-COR","Recruiting","No Results Available","Infection Viral","Other: nosocomial infection/hospital acquired infection","nosocomial infection","Hospices Civils de Lyon","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0214","March 9, 2020","October 10, 2020","October 30, 2020","March 2, 2020",,"March 13, 2020","Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04290780"
307,"NCT04281693","A New Screening Strategy for 2019 Novel Coronavirus Infection",,"Not yet recruiting","No Results Available","Novel Coronavirus Infection Pneumonia","Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","Screening accuracy|Cost-effectiveness analysis","Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital","All","Child, Adult, Older Adult","Not Applicable","230","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","307-nCoV","February 2020","March 2020","March 2020","February 24, 2020",,"February 24, 2020","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04281693"
308,"NCT04259892","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Cov-CONTACT","Recruiting","No Results Available","Coronavirus","Biological: 2019-nCoV PCR","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-06|2020-A00280-39","February 4, 2020","October 4, 2020","February 4, 2021","February 7, 2020",,"February 17, 2020","CIC 1425, Paris, France",,"https://ClinicalTrials.gov/show/NCT04259892"
309,"NCT04252274","Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV","DACO-nCoV","Recruiting","No Results Available","Pneumonia, Pneumocystis|Coronavirus","Drug: Darunavir and Cobicistat","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DACO-nCoV","January 30, 2020","August 31, 2020","December 31, 2020","February 5, 2020",,"March 4, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04252274"
310,"NCT04327804","A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research",,"Recruiting","No Results Available","SARS-CoV Infection","Diagnostic Test: Odd/Even birth year intervention groups","Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development","Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group","All","Child, Adult, Older Adult",,"120","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-002","March 25, 2020","April 3, 2020","April 10, 2020","March 31, 2020",,"March 31, 2020","Everett Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04327804"
311,"NCT04261517","Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )",,"Completed","No Results Available","Pneumonia, Pneumocystis|Coronavirus","Drug: Hydroxychloroquine","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC-nCoV","February 6, 2020","February 25, 2020","February 25, 2020","February 7, 2020",,"March 24, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04261517"
312,"NCT04321369","Impact of Swab Site and Sample Collector on Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals",,"Completed","No Results Available","Infections, Respiratory|Fever|Cough","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals","Accuracy of patient administered tests","Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group","All","Child, Adult, Older Adult",,"533","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","20-001","March 9, 2020","March 23, 2020","March 23, 2020","March 25, 2020",,"March 25, 2020","Everett Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04321369"
313,"NCT04251871","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection",,"Recruiting","No Results Available","Pneumonia Caused by Human Coronavirus (Disorder)","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment","Beijing 302 Hospital","All","14 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020001D","January 22, 2020","January 22, 2021","January 22, 2021","February 5, 2020",,"February 5, 2020","The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04251871"
314,"NCT04260308","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia",,"Recruiting","No Results Available","Virus; Pneumonia",,"GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)","Huazhong University of Science and Technology","All","Child, Adult, Older Adult",,"30000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRBID:TJ-C 20200107","February 3, 2020","April 15, 2020","April 20, 2020","February 7, 2020",,"February 7, 2020","Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04260308"
315,"NCT04275245","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoVs Infection Pneumonia","Drug: Meplazumab for Injection","2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status","Tang-Du Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200101","February 3, 2020","December 31, 2020","December 31, 2020","February 19, 2020",,"February 19, 2020","Tangdu Hospital, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT04275245"
316,"NCT04307459","Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life",,"Not yet recruiting","No Results Available","Coronavirus Infections|Respiratory Failure|Ventilator Lung","Other: standard operating procedures","Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management","University of Milan","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","02-PNSNP-2020","March 19, 2020","April 19, 2020","December 31, 2020","March 13, 2020",,"March 17, 2020","Luigi Sacco University Hospital, Milan, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT04307459"
317,"NCT04299152","Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2",,"Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR","Tianhe Stem Cell Biotechnologies Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","2020-TH-001","April 10, 2020","October 9, 2020","November 10, 2020","March 6, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04299152"
318,"NCT04322279","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)",,"Recruiting","No Results Available","Coronavirus","Diagnostic Test: Serology|Genetic: Sequencing","Number of Participants with positive serology in the 90 days following last contact|fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-16|2020-A00609-30","March 9, 2020","May 1, 2020","May 1, 2020","March 26, 2020",,"March 26, 2020","CIC 1425, Paris, France",,"https://ClinicalTrials.gov/show/NCT04322279"
319,"NCT04226157","Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *Due to COVID-19 Outbreak in United States the Investigators Have Paused All In-person Enrollment and Will Re-evaluate on May 1st*","HBPS","Recruiting","No Results Available","Ischemic Stroke|Hypertension","Device: Home Blood Pressure Monitoring Device (Qardio Arm)|Other: Primary Care Provider Blood Pressure Management","Feasibility of blood pressure self management in stroke survivors|Systolic Blood Pressure Difference","MedStar Georgetown University Hospital|Medstar Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-0718","February 21, 2019","December 31, 2020","March 31, 2021","January 13, 2020",,"March 19, 2020","Medstar Georgetown University Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04226157"
320,"NCT04335851","Video-Based Exercises and Well-Being During Social Isolation",,"Not yet recruiting","No Results Available","Social Isolation|Physical Inactivity|Well-Being","Other: Video based aerobic exercise","World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale","Biruni University|Istanbul University-Cerrahpasa","All","18 Years to 35 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Physical Activity Project","April 6, 2020","May 13, 2020","June 30, 2020","April 6, 2020",,"April 6, 2020","Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04335851"
321,"NCT04319211","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","COVID-19","Not yet recruiting","No Results Available","Healthy People","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale","Istanbul University-Cerrahpasa","All","18 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EAvcil|İpek Yeldan","March 25, 2020","May 15, 2020","July 20, 2020","March 24, 2020",,"March 24, 2020","Istanbul University Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04319211"
322,"NCT04328467","Pre-exposure Prophylaxis for SARS-Coronavirus-2",,"Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Drug: Hydroxychloroquine|Other: Placebo","COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","3500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rajasingham","April 1, 2020","August 2020","August 2020","March 31, 2020",,"April 6, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04328467"
323,"NCT04280913","Clinical Outcomes of Patients With COVID19",,"Withdrawn","No Results Available","Coronavirus Disease 2019","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital","All","Child, Adult, Older Adult",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GZHZ-COVID19","February 22, 2020","March 31, 2020","March 31, 2020","February 21, 2020",,"March 19, 2020","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04280913"
324,"NCT04333251","Study Testing Convalescent Plasma vs Best Supportive Care",,"Not yet recruiting","No Results Available","Pneumonia, Interstitial","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy","reduction in oxygen and ventilation support","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","020-123","April 1, 2020","December 31, 2022","December 31, 2022","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04333251"
325,"NCT04320056","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus|Pneumonia|Oxygen Toxicity","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay","Laval University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","21909","April 6, 2020","April 30, 2021","October 31, 2021","March 24, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04320056"
326,"NCT04320862","Pandemic Response Network",,"Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection",,"Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants","Duke University","All","Child, Adult, Older Adult",,"200000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105189","March 31, 2020","December 31, 2021","December 31, 2021","March 25, 2020",,"March 31, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04320862"
327,"NCT04280224","NK Cells Treatment for Novel Coronavirus Pneumonia",,"Recruiting","No Results Available","Novel Coronavirus Pneumonia","Biological: NK Cells","Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging","Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","xinxiangM","February 20, 2020","September 30, 2020","December 30, 2020","February 21, 2020",,"February 21, 2020","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China",,"https://ClinicalTrials.gov/show/NCT04280224"
328,"NCT04333875","Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","AS DEFER","Recruiting","No Results Available","Aortic Valve Stenosis","Device: TAVR or SAVR","Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00672","March 20, 2020","December 2020","December 2020","April 3, 2020",,"April 3, 2020","Department of Cardiology, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333875"
329,"NCT04244591","Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure","Steroids-SARI","Recruiting","No Results Available","Coronavirus Infections|Respiratory Infection Virus","Drug: methylprednisolone therapy|Other: Standard care","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Glucocorticoid nCoV","January 26, 2020","April 25, 2020","December 25, 2020","January 28, 2020",,"February 13, 2020","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04244591"
330,"NCT04316377","Norwegian Coronavirus Disease 2019 Study","NO COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Hydroxychloroquine Sulfate","Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)","Phase 4","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC 121446","March 25, 2020","April 1, 2021","March 3, 2025","March 20, 2020",,"April 3, 2020","Akershus University Hospital, Lørenskog, Norway",,"https://ClinicalTrials.gov/show/NCT04316377"
331,"NCT04276688","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",,"Recruiting","No Results Available","Novel Coronavirus Infection","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens","The University of Hong Kong|Hospital Authority, Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW-20-074","February 10, 2020","January 31, 2022","July 31, 2022","February 19, 2020",,"February 28, 2020","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04276688"
332,"NCT04319172","Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","COVIDSOT","Not yet recruiting","No Results Available","Transplant Recipient|Infections, Coronavirus",,"Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases|GESITRA-IC","All","16 Years and older   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDSOT","March 2020","March 2022","April 2022","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04319172"
333,"NCT03680274","Lessening Organ Dysfunction With VITamin C","LOVIT","Recruiting","No Results Available","Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus","Drug: Vitamin C|Other: Control","Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration","Université de Sherbrooke|Lotte & John Hecht Memorial Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-31-2019-2945","November 8, 2018","December 31, 2021","December 31, 2022","September 21, 2018",,"March 24, 2020","Research Center of the CHUS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03680274"
334,"NCT04326309","Audio Data Collection for Identification and Classification of Coughing",,"Recruiting","No Results Available","COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy",,"Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application","HealthMode Inc.","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HM070102","March 25, 2020","September 25, 2022","September 25, 2022","March 30, 2020",,"March 30, 2020","Virtual Facility, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04326309"
335,"NCT04308668","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","COVID-19 PEP","Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Drug: Hydroxychloroquine|Other: Placebo","Incidence of COVID19 Disease among those who are asymptomatic at trial entry|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 day","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00009267","March 17, 2020","April 21, 2020","May 12, 2020","March 16, 2020",,"April 3, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04308668"
336,"NCT04262921","Clinical Characterisation Protocol for Severe Emerging Infections","CCP-nCoV","Recruiting","No Results Available","Coronavirus Infections",,"Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","C20-05|2020-A00256-33","February 7, 2020","August 7, 2020","August 7, 2023","February 10, 2020",,"February 11, 2020","CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France|APHP La Pitié Salpêtrière, service des Maladies Infectieuses et Tropicales, Paris, France|APHP Bichat, Service de réanimation médicale et infectieuse, Paris, France|APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France",,"https://ClinicalTrials.gov/show/NCT04262921"
337,"NCT04329897","Acceptance and Commitment Therapy Delivered by Automated Software Messaging",,"Not yet recruiting","No Results Available","Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus","Behavioral: Software Messaging","Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","University of Iowa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201412701-1","March 31, 2020","May 30, 2020","June 30, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04329897"
338,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"February 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04276987"
